FEVER accompanied by a significant reduction in NEUTROPHIL count associated with CHEMOTHERAPY.
A decrease in the number of NEUTROPHILS found in the blood.
An abnormal elevation of body temperature, usually as a result of a pathologic process.
Hospital department responsible for the administration and provision of immediate medical or surgical care to the emergency patient.
Situations or conditions requiring immediate intervention to avoid serious adverse results.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Fever accompanied by a significant reduction in the number of NEUTROPHILS.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
BIOLOGIC PRODUCTS that are imitations but not exact replicas of innovator products.
The effort of two or more parties to secure the business of a third party by offering, usually under fair or equitable rules of business practice, the most favorable terms.
Economic sector concerned with the provision, distribution, and consumption of health care services and related products.
The confinement of a patient in a hospital.
Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Tumors or cancer located in bone tissue or specific BONES.
A plant genus of the family ORCHIDACEAE that is the source of the familiar flavoring used in foods and medicines (FLAVORING AGENTS).
A plant genus of the family Paeoniaceae, order Dilleniales, subclass Dilleniidae, class Magnoliopsida. These perennial herbs are up to 2 m (6') tall. Leaves are alternate and are divided into three lobes, each lobe being further divided into three smaller lobes. The large flowers are symmetrical, bisexual, have 5 sepals, 5 petals (sometimes 10), and many stamens.
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.
Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).

Mortality, length of stay, and cost associated with hospitalized adult cancer patients with febrile neutropenia. (1/10)

BACKGROUND: Febrile neutropenia (FN) is a serious complication following chemotherapy and is associated with significant mortality and financial expenditure. The aim of this study was to evaluate risk factors for longer length of stay (LOS) and mortality and cost of treatment among hospitalized adults with cancer who developed febrile neutropenia in Thailand. MATERIALS AND METHODS: Information on illness of inpatients and casualties came from hospitals nationwide and from hospital withdrawals from the 3 health insurance schemes in fiscal 2010. The data covered 96% of the population and were analyzed by age groups, hospital level, and insurance year schemes in patients with febrile neutropenia. RESULTS: A total of 5,809 patients were identified in the study. The mortality rate was 14%. The median LOS was 8.67 days and 69% of patients stayed for longer than 5 days. On bivariate analysis, age, cancer type, and infectious complications (bacteremia/sepsis, hypotension, fungal infections, and pneumonia) were significantly associated with longer LOS and death. On multivariate analysis, acute leukemia and infectious complications were linked with longer LOS and death significantly. The median cost of hospitalized FN was THB 33,686 (USD 1,122) with the highest cost observed in acute leukemia patients. CONCLUSIONS: FN in adult patients results in significant mortality in hospitalized Thai patients. Factors associated with increased mortality include older age (>70), acute leukemia, comorbidity, and infectious complications.  (+info)

Febrile neutropenia in the tropics: a description of clinical and microbiological findings and their impact on inappropriate therapy currently used at an oncological reference center in Colombia. (2/10)

 (+info)

Performance of serum biomarkers for the early detection of invasive aspergillosis in febrile, neutropenic patients: a multi-state model. (3/10)

 (+info)

Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. (4/10)

 (+info)

Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic. (5/10)

 (+info)

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. (6/10)

 (+info)

Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). (7/10)

 (+info)

Study design: two long-term observational studies of the biosimilar filgrastim Nivestim (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia. (8/10)

 (+info)

Nivestim 12 MU/ 0.2 ml solution for injection/infusion, Nivestim 30 MU/ 0.5 ml solution for injection/infusion, Nivestim 48MU/ 0.5 ml solution for injection/infusion - Summary of Product Characteristics (SmPC) by Hospira UK Ltd
TY - JOUR. T1 - Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors. AU - Lambertini, Matteo. AU - Ferreira, Arlindo R.. AU - Del Mastro, Lucia. AU - Danesi, Romano. AU - Pronzato, Paolo. PY - 2015/10/22. Y1 - 2015/10/22. N2 - Introduction: Neutropenia and febrile neutropenia are the most common and most severe bone marrow toxicities of chemotherapy. Recombinant granulocyte-colony stimulating factors (G-CSFs), both daily (filgrastim and biosimilars, and lenograstim) and long-acting (pegfilgrastim and lipegfilgrastim) formulations, are currently available to counteract the negative consequences of these side effects. Areas covered: The purpose of this article is to review the physiopathology of chemotherapy-induced febrile neutropenia and its consequences, and the current evidence regarding the pharmacological properties, clinical efficacy and cost-effectiveness of pegfilgrastim as a strategy to prevent chemotherapy-induced febrile ...
June 02, 2017 / 7:30 am, CEST Planegg/Munich, Germany, June 2, 2017. MorphoSys Starts Phase 3 Trial of MOR208 plus Bendamustine in Patients with Relapsed or Refractory DLBCL. First pivotal study with compound from MorphoSyss proprietary portfolio started, following IDMC recommendation after initial safety evaluation. MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that the pivotal phase 3 part of the B-MIND clinical study of MOR208 has been opened for enrollment. The randomized, multicenter phase 2/3 study is designed to investigate the efficacy of MOR208 plus bendamustine versus rituximab plus bendamustine in patients with relapsed or refractory diffuse large B cell lymphoma (R/R DLBCL) who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). DLBCL is the most common form of non-Hodgkins lymphoma. MOR208 is an investigational, Fc-enhanced monoclonal antibody directed against CD19 and is being developed for the ...
TORCH: A phase II study to determine the safety and efficacy of the dual mTORC inhibitor AZD2014 and to investigate additional toxicities in combination with rituximab in relapsed/refractory Diffuse Large B cell Lymphoma (DLBCL).
One of newest and most exciting approved treatments for cancer is the use of CAR-T therapy. CAR stands for chimeric antigen receptor and T stands for T-cell. Currently both Novartis (NVS) and Gilead (NASDAQ:GILD) have CAR-T therapies approved by the FDA. Axicabtagene (Yescarta) is sold by Gilead and is approved for refractory diffuse large b cell lymphoma(DLBCL). Refractory DLBCL is extremely difficult to treat with a complete response rate of only 7% and median survival of just over 6 months.. Axicabtagene was shown to have a complete response rate of 40%. Tisagenlucleucel (Kymriah) is sold by Novartis and was first approved for treating relapsed B-Cell Acute lymphoblastic leukemia. Both therapies cost north of $300,000 and must be given in a hospital inpatient setting.. A simple explanation of CAR-T therapy is that the patients own T cells are extracted, multiplied, and modified and then re-infused into the patient. These modified T cells then seek out and destroy cancer cells. CAR-T ...
This is a Phase 2, multi-center, open-label, single-arm study of the efficacy and safety of loncastuximab tesirine used as monotherapy in patients with relapsed or refractory DLBCL. The study will enroll approximately 140 patients. Loncastuximab Tesirine is an antibody drug conjugate (ADC) composed of a humanized antibody directed against human cluster of differentiation 19 (CD19), stochastically conjugated via a valine-alanine cleavable, maleimide linker to a pyrrolobenzodiazepine (PBD) dimer cytotoxin. Loncastuximab tesirine has been designed to target and kill CD19-expressing malignant B-cells.. A 2-stage design will be used in this clinical study, with an interim analysis for futility on the first 52 patients. If ≥10 patients respond (CR+PR), the study will proceed to complete full enrollment. Enrollment will continue during the interim analysis; however, further enrollment will be halted if futility is confirmed.. For each patient, the study will include a Screening Period (of up to 28 ...
BACKGROUND: Risk models of chemotherapy-induced (CIN) and febrile neutropenia (FN) have to date focused on determinants measured at the start of chemotherapy. We extended this static approach with a dynamic approach of CIN/FN risk modeling at the start of each cycle.. DESIGN: We applied predictive modeling using multivariate logistic regression to identify determinants of CIN/FN episodes and related hospitalizations and chemotherapy disturbances (CIN/FN consequences) in analyses at the patient (ever during the whole period of chemotherapy) and cycle-level (during a given chemotherapy cycle). Statistical dependence of cycle data being nested under patients was managed using generalized estimation equations. Predictive performance of each model was evaluated using bootstrapped c concordance statistics.. RESULTS: Static patient-level risk models of ever experiencing CIN/FN adverse events and consequences during a planned chemotherapy regimen included predictors related to history, risk ...
RESULTS: Mean age of the patients was 57 years. Mean absolute neutrophil count (ANC) was 436.8/mm3 (range: 0-1000/mm3). In all, 23 of the patients (22.5%) died due to complications related to FN. There were not a statistical difference in therapeutic outcome among tumor types, performance status, sex, depth of neutropenia, or time from emergency department presentationto initiation of antibiotic therapy ...
RESULTS: Mean age of the patients was 57 years. Mean absolute neutrophil count (ANC) was 436.8/mm3 (range: 0-1000/mm3). In all, 23 of the patients (22.5%) died due to complications related to FN. There were not a statistical difference in therapeutic outcome among tumor types, performance status, sex, depth of neutropenia, or time from emergency department presentationto initiation of antibiotic therapy ...
Kaliuresis (/ˌkæljʊərˈiːsɪs/, /ˌkæli-/) or kaluresis (/ˌkæljʊərˈiːsɪs/) is the condition of excreting potassium in the urine. Thiazide diuretics are used to treat patients with heart failure. Their goal is to decrease the amount of salt (sodium chloride) in the body by decreasing the amount that the kidney reabsorbs. This excess sodium in the kidneys that is destined for excretion via urination can cause hyponatremia (low sodium level) and can lead to kaliuresis by increasing sodium-potassium exchange. Natriuresis Harrisons Principles of Internal Medicine, 16th edition Merriam-Webster entry Welling, Paul A. Regulation of Renal Potassium Secretion: Molecular Mechanisms. Seminars in Nephrology. 33 (3): 215-228. doi:10.1016/j.semnephrol.2013.04.002 ...
TY - JOUR. T1 - Incorporating frailty in a multi-state model. T2 - Application to disease natural history modelling of adenoma-carcinoma in the large bowel. AU - Yen, Amy M F. AU - Chen, Tony H H. AU - Duffy, Stephen W.. AU - Chen, Chih Dao. PY - 2010/10. Y1 - 2010/10. N2 - Homogeneous multi-state models of disease progression have been widely used for designing and evaluating cancer screening programs. However, in screening for premalignant conditions of the cervix or large bowel, it is unlikely that all premalignant lesions have the same underlying propensity for progression. Incorporating frailty into multi-state models raises practical difficulties as it precludes the derivation of finite transition probabilities by matrix solution of the Kolmogorov equations. We address this problem by formulating a heterogeneous process as a series of homogeneous processes linked by transitions which are subject to heterogeneity (frailty). Continuous frailty and discrete mover-stayer models were developed. ...
Multi-state models provide a useful framework for estimating the rate of transitions between defined disease states and understanding the influence of covariates on transitions in studies of the disease progression. Statistical analysis of data from studies of disease progression often involves a number of challenges. A particular challenge is that the classification of the disease state may be subject to error. Another common problem is that there are many sources of heterogeneity in the data in which situation the assumption of time-homogeneous for common Markov models is not valid. In addition, it is common for discrete covariates subject to misclassification and the panel data collected from disease progression studies is time-dependence in the covariates. In Chapter 2, the progressive multi-state model with misclassification is developed to simultaneously estimate transition rates and account for potential misclassification. The performance of the maximum likelihood and pairwise likelihood ...
In May 2020, in the middle of SRAS-CoV-2 pandemic, the Chair and Secretary of the IDWP changed. Now, Rafael de la Camara (Madrid, Spain) is the Chair and Dina Averbuch (Jerusalem, Israel) is the new Secretary. We have to thank Dr Jan Styczynski and Dr Malgorzata Mikulska, previous Chair and Secretary, for the excellent work done in the previous four years with a characteristic friendly attitude.. SARS-CoV-2 pandemic has been an important focus for IDWP. At the early stage of the pandemic, the IDWP produced guidelines for the management of SARS-CoV-2 in SCT. The first one was released on March the 1st, and the last update (the 12th version) on December the 2nd, 2020.. As SARS-CoV-2 pandemic has broader implications for SCT and cellular therapies, that goes further from the infectious aspects, a COVID-19 task force has been created to have a holistic approach to the effects of the pandemic. The IDWP is part of this new task force.. In 2021 we are going to launch an annual online certificated ...
This work uses multi-state models of cancer disease progression to explore the misclassification of prostate cancer detected by screening or clinically. It aims to use different models, without or with a time component, to determine the sojourn time for a number of patients within an existing dataset. The outcomes should contribute to tailored approaches to screening for prostate cancer.. ...
Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation and Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH), Piñana, J. L., Xhaard, A., Tridello, G., Passweg, J., Kozijn, A., Polverelli, N., Heras, I., Perez, A., Sanz, J., Berghuis, D., Vázquez, L., Suárez-Lledó, M., Itäla-Remes, M., Ozcelik, T., Iturrate Basarán, I., Karakukcu, M., Al Zahrani, M., Choi, G., Cuesta Casas, M. A., Batlle Massana, M., Viviana, A., Blijlevens, N., Ganser, A., Kuskonmaz, B., Labussière-Wallet, H., Shaw, P. J., Arzu Yegin, Z., González-Vicent, M., Rocha, V., Ferster, A., Knelange, N., Navarro, D., Mikulska, M., de la Camara, R. & Styczynski, J., 29-Aug-2020, In : The Journal of Infectious Diseases.. Research output: Contribution to journal › Article › Academic › peer-review ...
His main clinical field is management of patients undergoing allogeneic stem cell transplantation. His research interests are in two major field: diagnosis and management of viral infections, including studies of antiviral drugs in immunocompromised patients and immunizations of the immunocompromised patient. He has held several elected positions in international scientific societies such as chair of the Infectious Diseases Working Party and secretary, European Society for Blood and Marrow Transplantation (EBMT), and council member, vice president, and president, International Immuncompromised Host Society. Prof. Ljungman has authored more than 300 peer-reviewed publications, several book chapters, and is also co-editor of the book Transplant Infections now in its 4th edition. ...
Survival Analysis of Patients with Gastric Cancer Undergoing Surgery at the Iran Cancer Institute: A Method Based on Multi-State Models Gastric cancer;intermediate event;multi-state model;proportional hazards model;survival rate; Background: Gastric cancer is one of the most common causes of cancer deaths all over the world and the most important reason for its high rate of death is its belated diagnosis at advanced stages of the disease. Events occur in patients which are regarded not only as themselves factors affecting patients survival but also which can be affected by other factors. This study was designed and implemented aiming to identify these events and to investigate factors affecting their occurrence. Materials and Methods: Data from 330 patients with gastric cancer undergoing surgery at the Iran Cancer Institute from 1995-1999 were analyzed. The survival time of these patients was determined after surgery and the effects of various factors including demographic, diagnostic and clinical as
In hospital-epidemiology the extended illness-death model, shown in Fig. 1, is a useful tool to study HAIs. The model allows both an etiological exploration of the events infection and in-hospital death and an investigation in terms of absolute risks.. In the extended illness-death model patients start in state 0 which is admission to the hospital. At this time none of the patients is infected. The patients remain in this state until they either leave the hospital without an HAI (state 2 if the discharge is alive, state 3 if the patient dies) or acquire an HAI. The concerned patients then move to state 1. In state 1 the patients remain under observation until discharge alive with an HAI (state 4) or death in the hospital with an HAI (state 5). The model is equivalent to the four-state model where death without and with an HAI are one state (state 3 and 5 are modelled as state 3) as well as discharge without and with an HAI (state 2 and 4 are modelled as state 2). In the four-state extended ...
Andersen, P. K., Borgan, O, Gill, R. D., Keiding, N. Statistical Models Based on Counting Processes. Springer-Verlag, (1993).. Kalbfleisch, J. D., and R. L. Prentice. The Statistical Analysis of Failure Time Data. 2nd ed. New York: Wiley, (2002).. Per Kragh Andersen and Niels Keiding. Multi-state models for event history analysis. Statistical Methods in Medical Research 2002; 11: 91-115.. Per Kragh Andersen, Steen Z Abildstrom, Susanne Rosthøj. Competing risks as a multi-state model. Statistical Methods in Medical Research 2002; 11: 203-215.. ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Please join the RARE Portal to add diseases of interest to your personal profile. By creating a profile, you can receive news, resources and updates related to this disease as well as many other benefits. ...
Key clinical point: Risk factors for chemotherapy-induced febrile neutropenia include corticosteroid use and intravenous antibiotics.Major finding: Corticosteroid use was associated with an increased risk of febrile neutropenia, compared with no corticosteroid use (hazard ratio, 1.53; P less than .01).Study details: This retrospective study included 15,971 patients with non-Hodgkin lymphoma or five solid tumors.
Plasma viscosity estimation is a reflection of changes in plasma proteins within the blood. The values from normal subjects are within a narrowly defined range and change when protein fractions are altered. The major influence on plasma viscosity is exerted by fibrinogen and immunoglobulins. The Viscometer determines viscosity by measuring the resistance of the plasma flow through a capillary under a constant vacuum ...
The absolute risk reduction by prophylaxis in chemotherapy-induced febrile neutropenia (FN) is largest in patients at highest underlying risk. Therefore, reliable predictive models are needed. Here, we develop and validate such a model for risk of FN during chemotherapy cycles 2-6. A prediction score for risk of FN during the first cycle has recently been published1 . Patients with solid cancers initiating first-line chemotherapy in 2010-2016 were included. Cycle-specific risk factors were assessed by Poisson regression using generalised estimating equations and random split-sampling. The derivation cohort included 4,590 patients treated with 15,419 cycles, wherein 326 (2.1%) FN events occurred. Predictors of FN in multivariable analyses were: higher predicted risk of FN in the first cycle, platinum- or taxane-containing therapies, concurrent radiotherapy, treatment in cycle 2 compared to later cycles, previous FN or neutropenia, and not receiving granulocyte colony-stimulating factors. Each ...
Chemotherapy-induced febrile neutropenia (FN) predisposes patients to life-threatening infections and typically requires hospitalization. The goal was to investigate whether a risk assessment tool aligned with national guidelines could help identify patients at risk of FN and reduce FN-related hospitalizations. Beginning in October 2004, oncology nurses applied the new risk assessment tool to all patients initiating chemotherapy or a new regimen. Patients at risk for FN received prophylactic colony-stimulating factor. Charts for 189 patients receiving chemotherapy in fiscal year 2005 (FY05) were compared with charts of 155 patients receiving chemotherapy in FY04, before the tool was implemented. The incidence of FN-related hospitalization declined by 78%, from 9.7% in FY04 to 2.1% in FY05 (P = .003). Total hospital days decreased from 117 to 24. Routine systematic evaluation by oncology nurses improves recognition of patients at risk of FN and substantially reduces FN-related hospitalization.
Snowden JA, Hawkey C, Hind D, Swaby L, Mellor K, Emsley R, Mandefield L, Lee E, Badoglio M, Polge E, Labopin M, Gribben J, Pockley AG, Foulds GA, Lobo A, Travis S, Parkes M, Satsangi J, Papaioannou D, Lindsay JO; Autologous Stem Cell Transplantation In Refractory CD - Low Intensity Therapy Evaluation Study Investigators; European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP ...
Daikeler T, Labopin M, Di Gioia M, Abinun M, Alexander T, Miniati I, Gualandi F, Fassas A, Martin T, Schwarze CP, Wulffraat N, Buch M, Sampol A, Carreras E, Dubois B, Gruhn B, Güngör T, Pohlreich D, Schuerwegh A, Snarski E, Snowden J, Veys P, Fasth A, Lenhoff S, Messina C, Voswinkel J, Badoglio M, Henes J, Launay D, Tyndall A, Gluckman E, Farge D. Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood. 2011 Aug 11;118(6):1693- ...
Maximized multi-state compaction and more tolerance in memory state behavior is achieved through a flexible, self-consistent and self-adapting mode of detection, covering a wide dynamic range. For high density multi-state encoding, this approach borders on full analog treatment, dictating analog techniques including A to D type conversion to reconstruct and process the data. In accordance with the teachings of this invention, the memory array is read with high fidelity, not to provide actual final digital data, but rather to provide raw data accurately reflecting the analog storage state, which information is sent to a memory controller for analysis and detection of the actual final digital data.
Maximized multi-state compaction and more tolerance in memory state behavior is achieved through a flexible, self-consistent and self-adapting mode of detection, covering a wide dynamic range. For high density multi-state encoding, this approach borders on full analog treatment, dictating analog techniques including A to D type conversion to reconstruct and process the data. In accordance with the teachings of this invention, the memory array is read with high fidelity, not to provide actual final digital data, but rather to provide raw data accurately reflecting the analog storage state, which information is sent to a memory controller for analysis and detection of the actual final digital data.
Note: An important Network software prerequisite is fully aligned sequence data (the same applies for other phylogenetic software like TCS). Please use the DNA Alignment software for aligning FASTA data and for correctly formatting these into Network binary rdf or Network multi-state rdf files ...
After introducing the main topic of this paper (the study of purchase incidence and brand choice decisions) we explain basic concepts of hazard models and describe the probability distributions considered in the empirical study presented later. After a review of pure purchase incidence (product category) models as well as integrated models that include brand choice as well, we specify and discuss properties of one-state and multi-state hazard models, respectively. Our conclusions are based on applying hazard models to household scanner data. ...
Health,... Nursing Home Workers in PA MI IL FL OH MD WI WA Join Forces ... Buyout ...WASHINGTON Oct. 3 -- In an effort to improve...In states where Manor Care has large operations includingPennsylvani...,SEIU,Launches,Multi-State,Grassroots,Campaign,Calling,on,the,Carlyle,Group,to,Put,Care,Above,Profits,in,Buyout,of,Nations,Largest,Nursing,Home,Chain,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
Dr Piero OlliaroHead of intervention and implementation research at TDRFormer member of the Drugs for Neglected Diseases working groupPiero Olliaro earned his M
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
The cost of the conference is $65 ($70 after Feb. 7) for the first person from each farm and $55 ($65 after Feb. 7) for each additional person from the farm. This fee includes registration, breaks, trade show, proceedings and Tuesday lunch. The (optional) dinner on Monday evening is $15 ...
Visit For Sample Pages:. https://www.delveinsight.com/sample-request/chemotherapy-induced-febrile-neutropenia-market. Key Benefits of Chemotherapy Induced Febrile Neutropenia Market Report. Chemotherapy Induced Febrile Neutropenia market report provides an in-depth analysis of Chemotherapy Induced Febrile Neutropenia Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.. The Chemotherapy Induced Febrile Neutropenia market report will help in developing business strategies by understanding the Chemotherapy Induced Febrile Neutropenia Market trends & developments, key players and future market competition that will shape and drive the Chemotherapy Induced Febrile Neutropenia market in the upcoming years.. The Chemotherapy Induced Febrile Neutropenia market report covers Chemotherapy Induced Febrile Neutropenia current treatment practices, emerging drugs, market share of the ...
The U.S. Department of Health and Human Services announced today the appointment of 14 members to the new Tick-Borne Disease Working Group.
TY - JOUR. T1 - First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer. T2 - A multicenter, double-blind, placebo-controlled phase III study. AU - Vogel, Charles. AU - Wojtukiewicz, Marek Z.. AU - Carroll, Robert R.. AU - Tjulandin, Sergei A.. AU - Barajas-Figueroa, Luis Javier. AU - Wiens, Brian L.. AU - Neumann, Theresa A.. AU - Schwartzberg, Lee S.. PY - 2005/2/20. Y1 - 2005/2/20. N2 - Purpose: We evaluated the efficacy of pegfilgrastim to reduce the incidence of febrile neutropenia associated with docetaxel in breast cancer patients. Patients and Methods: Patients were randomly assigned to either placebo or pegfilgrastim 6 mg subcutaneously on day 2 of each 21-day chemotherapy cycle of 100 mg/m2 docetaxel. The primary end point was the percentage of patients developing febrile neutropenia (defined as body temperature ≥ 38.2°C and neutrophil count , 0.5 × 109/L on the same day of the fever or the day after). Secondary end points were ...
Ronald Gangnon is Professor of Biostatistics with a joint appointment in the Department of Population Health Sciences and the Department of Biostatistics & Medical Informatics. He also has an affiliate appointment in the Department of Statistics. Dr. Gangnon earned his BA degree in Mathematics and Economics at the University of Minnesota-Duluth (1992) and his MS (Statistics, 1994) and PhD (Statistics with emphasis in Biostatistics, 1998) from the University of Wisconsin-Madison. Dr. Gangnons research interests are in the development and application of statistical methods in clinical and epidemiologic research. Areas of methodologic interest include spatial epidemiology, with emphasis on detection and modeling of spatial and spatio-temporal clusters, syndromic surveillance, age-period-cohort modeling, multi-state models and ranking. Dr. Gangnon serves as Director of the Biostatistics Core for the Childhood Origins of ASThma (COAST) project, a prospective birth cohort study of early childhood ...
Downloadable! multistate provides a set of commands for multi-state survival analysis. This includes msset, a data preparation tool which converts a dataset from wide (one observation per subject, multiple time and status variables) to long (one observation for each transition of which a subject is at risk), and predictms, which calculates transition probabilities, and many other useful measures of absolute risk, following the fit of a model using streg, or stpm2. predictms allows different families of models to be specified for each transition. All quantities are calculated through simulation, including confidence intervals. Differences and ratios across covariate patterns can be calculated.
Beth Carrison, co-founder of Tick-Borne Conditions United, delivered these remarks to the Tick-Borne Disease Working Group on July 8.
[Febrile neutropenia is one of the most feared complications of anti-tumor therapy. It can either herald potentially fatal infection or contribute to suboptimal dose-intensity of cancer treatment. Optimal management of affected patients is based upon a multi-disciplinary approach dependent on several factors. Knowledge on institutional epidemiology and predefi ned management strategies improve quality and outcome of anti-infective therapy. In an era of more and more resistant pathogens and erosion of the antimicrobial armamentarium clinicians taking care of cancer patients carry increased responsibility in their professional activity. Here questions of practical importance related to prevention and therapy of neutropenic infections are outlined.]
Amgen Inc. - Barcelona, Spain, June 14, 2010 (ots/PRNewswire) - Data presented at the 15th European Hematology Association (EHA) congress in Barcelona, highlights the impact of febrile neutropenia (FN) on chemotherapy delivery in non-Hodgkin ...
Febrile Neutropenia. On-line free medical diagnosis assistant. Ranked list of possible diseases from either several symptoms or a full patient history. A similarity measure between symptoms and diseases is provided.
Learn about a GCS-F indicated to help reduce the incidence of infection manifested by febrile neutropenia (FN) in patients at risk of FN.
CLEVELAND - Twelve defendants were indicted Tuesday in a major drug trafficking conspiracy in which large shipments of cocaine were flown by private chartered airplanes from Texas to Cleveland....
After undergoing screening procedures to confirm that you are eligible to participate in the research study you will be admitted to the hospital. You will likely receive the majority of treatment on an inpatient basis. You will remain in the hospital for at least Days 4-8 and will be discharged at the discretion of your study doctor. It is likely that you will be hospitalized for several weeks due to the risk of infection after chemotherapy.. Since we are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have relapsed or refractory AML, not everyone who participates in this research study will receive the same dose of the study drug. The dose you get will depend on the number of participants who have been enrolled in the study before you and how well they have tolerated their doses.. If you take part in this study you will be given a study drug-dosing calendar. There is only one cycle of treatment, ...
Buoyed by cheering crowds and bolstered by more than $1.3 million a day in TV ads, candidates made their last pleas for votes before the multi-state contests begin.
Neulasta is approved as a treatment for patients undergoing chemotherapy, to decrease the incidence of infection by febrile neutropenia. It is administered...
Abraham, I., MacDonald, K., Song, M.K., Ciesielski, G., Pacheco, C., Lee, C., Cholette, M., Kinsey, K., Speaks, P., Hermans, C., Brié, H., Reel, S., Van der Niepen, P., Yee, B., & Vancayzeele, S. (in press). Patient- and physician-level determinants of blood pressure response to treatment in normal and overweight patients. (the PREVIEW Study). Nutrition, Metabolism, & Cardiovascular Diseases.. Aapro, M., Cornes, P., & Abraham, I. (in press). Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. Journal of Oncology Pharmacy Practice.. Gesualdo, L., London, G., Turner, M., Lee, C., MacDonald, K., Covic, A., Zaoui, P., Combe, C., Dellana, F., Muenzberg, M., & Abraham, I. (in press). A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anemia in hemodialysis patients: ...
We present a pooled update of two large, multicenter MM-009 and MM-010 placebo-controlled randomized phase III trials that included 704 patients and assessed lenalidomide plus dexamethasone versus dexamethasone plus placebo in patients with relapsed/refractory multiple myeloma (MM). Patients in both studies were randomized to receive 25 mg daily oral lenalidomide or identical placebo, plus 40 mg oral dexamethasone. In this pooled analysis, using data up to unblinding (June 2005 for MM-009 and August 2005 for MM-010), treatment with lenalidomide plus dexamethasone significantly improved overall response (60.6 vs 21.9%, P|0.001), complete response rate (15.0 vs 2.0%, P|0.001), time to progression (median of 13.4 vs 4.6 months, P|0.001) and duration of response (median of 15.8 months vs 7 months, P|0.001) compared with dexamethasone-placebo. At a median follow-up of 48 months for surviving patients, using data up to July 2008, a significant benefit in overall survival (median of 38.0 vs 31.6 months, P=0
Between Nov 8, 2007, and June 9, 2010, 125 patients were enrolled and underwent randomisation. 119 patients comprised the per-protocol population and were randomly assigned to receive either lenalidomide plus dexamethasone (n=57) or observation (n=62). The cutoff date for this update was June 30, 2015. Median follow-up for surviving patients was 75 months (IQR 67-85).. Lenalidomide plus dexamethasone continued to provide a benefit on time to progression compared with observation (median time to progression not reached [95% CI 47 months-not reached] vs 23 months [16-31]; hazard ratio [HR] 0·24 [95% CI 0·14-0·41]; p,0·0001). Progression to multiple myeloma occurred in 53 (86%) of 62 patients in the observation group compared with 22 (39%) of 57 patients in the treatment group. At data cutoff, ten (18%) patients had died in the treatment group and 22 (36%) patients had died in the observation group; median overall survival from the time of study entry had not been reached in either group (95% ...
The Tick-Borne Disease Working Group was established by the 21st Century Cures Act to improve federal coordination of efforts related to tick-borne diseases. Members will review all U.S. Department of Health and Human Services efforts related to tick-borne diseases to provide expertise and help ensure interagency coordination and minimize overlap, examine research priorities, and identify unmet needs.. HHS Tick-Borne Disease Working Group Web Page. ...
The deaths of countless puppies might soon be prevented, thanks to a newly tested monoclonal antibody.. A study conducted by Kindred Biosciences has demonstrated 100 percent efficacy in the prevention of canine parvovirus (CPV), as well as a mortality benefit in the treated group, the company says.. In a randomized, blinded, study, half of a sample group received a placebo, while the other half were administered KIND-030, a monoclonal antibody that binds to portions of CPV and prevents it from entering cells.. None of the canines treated with the product developed the disease, KindredBio says, while all of the placebo-control dogs developed parvovirus infection as predefined in the study protocol.. These positive study results provide hope for the first time to dogs exposed to this deadly disease, says the companys director of clinical development, Beth Kee, DVM.. CPV typically affects unvaccinated puppies younger than six months old, but it can occur in unvaccinated dogs of all ages. ...
Lyme Disease Association was founded in 1991 with a mission of expanding research and funding for Lyme Disease nation wide. Visit our site to find out more.
The FDA approved IXIFI based on the overall results obtained during the multi-national, randomised, double blind, two-arm, parallel group Phase III REFLECTIONS B537-02 trial conducted in subjects with moderate-to-severe active rheumatoid arthritis.. Results indicated high degree of similarity between IXIFI and the reference product Remicade, which was given as an intravenous injection combined with methotrexate.. Performed to assess the safety, efficacy and immunogenicity of IXIFI, the trial met its primary endpoint of ACR20 response at week 14.. Outside the US, Pfizer markets three biosimilar medicines, INFLECTRA (infliximab), Retacrit (epoetin zeta) and Nivestim (filgrastim).. In addition, the firms portfolio includes a biosimilars pipeline with 13 distinct biosimilar molecules that are in different stages of development.. The firm also markets Celltrions INFLECTRA (infliximab-dyyb) in select markets, including the US.. ...
A new study comparing 2 risk stratification models found that the Clinical Index of Stable Febrile Neutropenia (CISNE) Model is useful for identifying low-risk patients with febrile neutropenia, but the combination of the CISNE Model with the Multinational Association of Supportive Care in Cancer Risk Index Score may help emergency physicians cope with febrile neutropenia more confidently.
Small RNAs (sRNAs) can operate as regulatory agents to control protein expression by interaction with the 5 untranslated region of the mRNA. We have developed a physicochemical framework, relying on base pair interaction energies, to design multi-state sRNA devices by solving an optimization problem with an objective function accounting for the stability of the transition and final intermolecular states. Contrary to the analysis of the reaction kinetics of an ensemble of sRNAs, we solve the inverse problem of finding sequences satisfying targeted reactions. We show here that our objective function correlates well with measured riboregulatory activity of a set of mutants. This has enabled the application of the methodology for an extended design of RNA devices with specified behavior, assuming different molecular interaction models based on Watson-Crick interaction. We designed several YES, NOT, AND, and OR logic gates, including the design of combinatorial riboregulators. In sum, our de novo approach
Health,... HARRISBURG Pa. March 18 -- Attorney Gene...Corbett said the settlement follows a joint federal and stateinvestig...According to the settlement CVS was accused of making wholesalechang...Corbett said that Pennsylvania will receive $495628 from CVS/Caremark...,Attorney,General,Corbett,Announces,$36.7,Million,Multi-State,Settlement,With,CVS/Caremark,in,National,Dosage-Switching,Investigation,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
Febrile neutropenia is defined as: (1) a single oral temperature above 38.3°C or a temperature of 38.0°C or higher lasting longer than 1 h, and (2) an absolute neutrophil count below 500 cells/^l (Hughes et al. 2002). Of bladder cancer patients undergoing CMV or MVAC chemotherapy regimens, 10 % -14 % meet these established criteria (Gilligan et al. 2003). The importance of febrile neutropenia lies in the fact that infection is the most common cause of fever in the neutropenic setting (50 %) and, in turn, the leading cause of chemotherapy-related death (Schimpff 1986). As such, fever in the context of neutropenia is considered to reflect active infection until proven otherwise.. Was this article helpful?. ...
Pegfilgrastim was evaluated in three randomized, double-blind, controlled studies. Studies 1 and 2 were active-controlled studies that employed doxorubicin 60 mg/m2 and docetaxel 75 mg/m2 administered every 21 days for up to 4 cycles for the treatment of metastatic breast cancer. Study 1 investigated the utility of a fixed dose of pegfilgrastim. Study 2 employed a weight-adjusted dose. In the absence of growth factor support, similar chemotherapy regimens have been reported to result in a 100% incidence of severe neutropenia (ANC , 0.5 x 109/L) with a mean duration of 5 to 7 days and a 30% to 40% incidence of febrile neutropenia. Based on the correlation between the duration of severe neutropenia and the incidence of febrile neutropenia found in studies with filgrastim, duration of severe neutropenia was chosen as the primary endpoint in both studies, and the efficacy of pegfilgrastim was demonstrated by establishing comparability to filgrastim-treated patients in the mean days of severe ...
Pegfilgrastim was evaluated in three randomized, double blind, controlled studies. Studies 1 and 2 were active-controlled studies that employed doxorubicin 60 mg/m2 and docetaxel 75 mg/m2 administered every 21 days for up to 4 cycles for the treatment of metastatic breast cancer. Study 1 investigated the utility of a fixed dose of Pegfilgrastim. Study 2 employed a weight-adjusted dose. In the absence of growth factor support, similar chemotherapy regimens have been reported to result in a 100% incidence of severe neutropenia (ANC , 0.5 x 109/L) with a mean duration of 5 to 7 days and a 30% to 40% incidence of febrile neutropenia. Based on the correlation between the duration of severe neutropenia and the incidence of febrile neutropenia found in studies with filgrastim, duration of severe neutropenia was chosen as the primary endpoint in both studies, and the efficacy of Pegfilgrastim was demonstrated by establishing comparability to filgrastim-treated patients in the mean days of severe ...
DCE coordinates the WHO Communicable Diseases Working Group on Emergencies (CD-WGE), which includes WHO experts across many departments on relevant diseases. The CD-WGE provides expert advice for the development of guidelines and training material, and helps set standards and prioritize interventions for communicable diseases in acute and protracted humanitarian emergencies. ...
Skip Anderson, MD, FACC has been working to build a database of speakers who can respond to invitations to the College from our international colleagues and facilitate collaboration and learning on an international level. Dr. Anderson has also asked for volunteers to help in this endeavor, which is strongly endorsed by the ACC.. The council is also in the early stages of forming a structural heart disease working group, led by Joaquin Cigarroa, MD, FACC. This is a heart team concept and will include members with collaborative special interests outside of interventional cardiology, including but not limited to: general cardiologists, adult congenital cardiologists, cardiac surgeons, echocardiography/imaging specialists, electrophysiologists, cardiovascular team members, fellows in training, and anesthesiologists.. The council and section would like to continue to see a strong relationship between the ACC (aka, House of Cardiology) and Society for Cardiac Angiography and Interventions (SCAI) (aka, ...
PENGGUNAAN ANTIBIOTIKA PADA PASIEN LEUKEMIA AKUT DEWASA DENGAN FEBRILE NEUTROPENIA SETELAH PEMBERIAN KEMOTERAPI AGRESIF DI RUMAH SAKIT KANKER DHARMAIS JAKARTA
TF=Transcription Factor; Ch=Channel; GPCR=GPCR; CA=Cell Adhesion; EM=Extracellular Matrix; SP=Structural Protein; Ng=Neurogenesis; Hox=Homeobox; NR=Nuclear Receptor; NH/NT=NH/NT; AG=Axon Guidance; SLC=SLC Transporter; Fox=Forkhead ...
Proper localization of newly synthesized proteins is essential to cellular function. Among different protein localization modes, the signal recognition particle (SRP) and SRP receptor (SR) constitute the conserved targeting machinery in all three life kingdoms and mediate about one third of the protein targeting reactions. Based on experimental and computational studies, a detailed molecular model is proposed to explain how this molecular machinery governs the efficiency and fidelity of protein localizations. In this targeting machinery, two distinct SRP GTPases are contained into the SRP and SR that are responsible to the interactions between SRP and SR. These two GTPases can interact with one another through a series of sequential and discrete interaction states that are the early intermediate formation, stable complex association, and GTPase activation. In contrast to canonical GTPases, a floppy and open conformation adopted in free SRP GTPases can facilitate efficient GTP/GDP exchange ...
March 2020, Hannover, Germany - Even in times of the SARS-CoV-2/COVID-19 pandemic, the donation and transplantation of tissues such as the cornea of the eye can be carried out. With an adapted donor screening, further precautions and the commitment of about 80 employees, the German Society for Tissue Transplantation (DGFG) maintains the supply of safe…. Read more. ...
This study was aimed to evaluate of febrile neutropenia in patients receiving chemotherapy and find out its association with haematological parameters.
DI-fusion, le Dépôt institutionnel numérique de lULB, est loutil de référencementde la production scientifique de lULB.Linterface de recherche DI-fusion permet de consulter les publications des chercheurs de lULB et les thèses qui y ont été défendues.
Frustrated by inaction in Washington, Florida officials this week are asking other states to join them in setting up an insurance catastrophe fund.If established, a multi-state fund would bail out
Whether its a multi-state road trip or a weekend drive to the lake, you want to be prepared for whatever you might encounter on the road. Heres a list of emergency kit essentials to keep in your vehicle.
Na2HPO4 • 2H2O, M. wt. 178.05; 0.2M-solution contains 35.61 g/l. Na2HPO4 • 12H2O, M. wt. 358.22; 0.2M -solution contains 71.64 g/l. NaH2PO4 • H2O, M. wt. 138.01; 0.2M-solution contains 27.6 g/l. NaH2PO4 • 2H2O, M. wt. 156.03; 0.2M-solution contains 31.21 g/l ...
About Endo-ERN , Endo-ERN, About the Network Endo-ERN aims to improve access to high-quality healthcare for patients with hormonal disorders. For this purpose the education of Reference Centers (RCs) across Europe will be supported
Remedial treatments to deal with chemotherapy-induced toxicities is through injection of granulocyte colony-stimulating factor ... specifically with observed febrile neutropenia, neurotoxicity, ototoxicity, and nephrotoxicity. ... For systemic chemotherapy (issued orally or intravenously), the regimen is standardised in every FIGO staging to comprise ... With a recurrence up to 15-25% for early-stage patients, adjuvant chemotherapy needs to couple with surgical resection of tumor ...
Fermented wheat germ extract reduces chemotherapy-induced febrile neutropenia in pediatric cancer patients. J Pediatric Hematol ... Fermented wheat germ extract induces apoptosis and downregulation of major histocompatibility complex class I proteins in tumor ...
... concentrations are early predictors of septic shock development in patients with post chemotherapy febrile neutropenia". BMC ... This quiescence or slow cell cycling of HSCs induced by Tie-2/Ang-1 signaling contributes to the maintenance of long-term ... It has been also implicated to play role in hepatocellular and endometrial carcinoma-induced angiogenesis. Experiments using ... 2013). "Kaposi's sarcoma-associated herpesvirus induces rapid release of angiopoietin-2 from endothelial cells". J Virol. 87 ( ...
Use of anthracyclines has also been shown to be significantly associated with cycle 1 severe or febrile neutropenia. Other ... Angsutararux P, Luanpitpong S, Issaragrisil S (2015). "Chemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative ... It was first recognised to be related to the oxidative stress induced by anthracyclines. A more recent explanation has emerged ... Cytotoxicity is primarily due to inhibition of topoisomerase II after the enzyme induces a break in DNA, preventing religation ...
Haematological adverse effects include neutropenia (95.5%), anaemia (90.4%), febrile neutropenia (11.0%) and thrombocytopenia ( ... As with all chemotherapy, adverse effects are common, and many side effects have been documented. Because docetaxel is a cell- ... When used with anticonvulsants, which induce CYP3A4, an increased dose of docetaxel may be required. Pre-treatment with ... It may be used by itself or along with other chemotherapy medication. It is given by slow injection into a vein. Common side ...
Causes of neutropenia include chemotherapy and bone marrow transplantation. Filgrastim is also used to increase the number of ... Shortly after it was introduced, analyses of whether filgrastim is a cost-effective way of preventing febrile neutropenia ... Moore DC, Pellegrino AE (September 2017). "Pegfilgrastim-Induced Bone Pain: A Review on Incidence, Risk Factors, and Evidence- ... Exploration of Risk Factors for Febrile Neutropenia". Supportive Cancer Therapy. 3 (1): 36-46. doi:10.3816/SCT.2005.n.023. PMID ...
... reduction in the duration of neutropenia and the incidence of febrile neutropenia in adults treated with cytotoxic chemotherapy ... "Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients". Biologics. 10: 1-8. doi:10.2147/BTT. ... is a medication used to reduce the duration of neutropenia and the incidence of febrile neutropenia in adults. It is given by ... treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia ...
Common adverse effects with cabazitaxel include neutropenia (including febrile neutropenia) and GIT side effects appeared ... September 2011). "Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in ... However, C20 and C25 did not demonstrate superiority for OS versus D75 in patients with chemotherapy-naïve mCRPC. Cabazitaxel ... Cabazitaxel was associated with more grade 3-4 neutropenia (81.7%) than mitoxantrone (58%). ...
... is frequently given in the treatment of febrile neutropenia. This condition frequently occurs in patients with ... Margolin, L (2004). "Impaired rehabilitation secondary to muscle weakness induced by meropenem". Clinical Drug Investigation. ... Antimicrobial Agents and Chemotherapy. 54 (7): 2974-8. doi:10.1128/AAC.01582-09. PMC 2897321. PMID 20479205. Yu Z, Pang X, Wu X ... Journal of Antimicrobial Chemotherapy. 72 (3): 782-790. doi:10.1093/jac/dkw476. PMC 5890718. PMID 27999041. "Hefny Pharma Group ...
A neutropenic fever, also called febrile neutropenia, is a fever in the absence of normal immune system function.[citation ... it is sometimes difficult to determine a febrile stage.[citation needed] Fever can also be behaviorally induced by ... This kind of fever is more commonly seen in people receiving immune-suppressing chemotherapy than in apparently healthy people ... Rarely a fever may trigger a febrile seizure, with this being more common in young children. Fevers do not typically go higher ...
... has been shown in three clinical trials to significantly reduce the occurrence of chemotherapy-induced neutropenia and the ... when combined with profound neutropenia (febrile neutropenia), is considered a medical emergency and requires broad spectrum ... neutropenia, cyclic neutropenia, autoimmune neutropenia, and congenital neutropenia.[medical citation needed] Neutropenia that ... drug-induced neutropenia). Additionally, acute neutropenia can be commonly seen from people recovering from a viral infection ...
1997). Febrile Neutropenia. Berlin, Heidelberg: Springer Berlin Heidelberg. doi:10.1007/978-3-642-60443-0. ISBN 978-3-540-61230 ... Allergic reactions can be induced from the side chains of β-lactam antibiotics such as amoxicillin, or antibodies surrounding ... Piperacillin/tazobactam Nosocomial Pneumonia Study Group". The Journal of Antimicrobial Chemotherapy. 43 (3): 389-97. doi: ... A dosage of 90mg/kg every 6 hours is suggested for infants and children diagnosed with neutropenia. Common side effects ...
... has been studied as an alternative to vancomycin in the treatment of febrile neutropenia in cancer patients when Gram ... Long-term use of linezolid has also been associated with chemotherapy-induced peripheral neuropathy, a progressive and enduring ... del Pino BM (23 February 2010). "Chemotherapy-induced Peripheral Neuropathy". NCI Cancer Bulletin. 7 (4): 6. Archived from the ... Chemotherapy drugs associated with CIPN include thalidomide, the epothilones such as ixabepilone, the vinca alkaloids ...
... characterized by neutropenia and fever) is similar to the one used for other febrile neutropenic patients. However, important ... Ingestion of radioactive materials caused many radiation-induced cancers in the 1930s, but no one was exposed to high enough ... Journal of Antimicrobial Chemotherapy. 33 (1): 63-74. doi:10.1093/jac/33.1.63. ISSN 1460-2091. PMID 8157575. Patchen ML, Brook ... Individuals that develop neutropenia after exposure to radiation are also susceptible to irradiation damage in other tissues, ...
Febrile neutropenia (fever due to decrease in white blood cells) occurs in 10 to 14% and death due to toxicity in about 3-4%. ... cisplatin-based chemotherapy Metastatic disease but unfit for cisplatin-based chemotherapy: carboplatin-based chemotherapy ... Schistosoma eggs induces a chronic inflammatory state in the bladder wall resulting in tissue fibrosis. Higher levels of N- ... Role of adjuvant chemotherapy (chemotherapy after main treatment) is limited to people with high grade tumours (pT3/T4and/or N+ ...
Chemotherapy-induced hyperpigmentation Drug-induced acne Drug-induced angioedema Drug-related gingival hyperplasia Drug-induced ... Cyclic neutropenia Desquamative gingivitis Drug-induced ulcer of the lip Epidermization of the lip Epulis Epulis fissuratum ( ... Wallach D, Vignon-Pennamen MD (2006). "From acute febrile neutrophilic dermatosis to neutrophilic disease: forty years of ... induced Hair dye-induced Hair lotion-induced Hair spray-induced Hair straightener-induced Hair tonic-induced Houseplant-induced ...
... and a significant reduction in febrile neutropenia. These findings could have major implications for treating patients with ... Anthracyclines are important chemotherapy agents. However, their use is associated with irreversible and cumulative heart ... Pixantrone inhibits antigen specific and mitogen induced lymphomononuclear cell proliferation, as well as IFN-gamma production ... randomized clinical trial studied pixantrone to see how well it works compared to other chemotherapy drugs in treating patients ...
Febrile neutropenia, Friedreich's ataxia (T), Gastrointestinal bleeding, Gastroesophageal reflux disease, Gaucher's disease, ... Heparin-induced thrombocytopenia (T, good article since 1 January 2010), Hereditary hemorrhagic telangiectasia (T, good article ... Chemotherapy, Colchicine, Danazol (T), Dantrolene (T), Demeclocycline, Desiccated thyroid extract, Dexamethasone, Doxapram, ... Coeliac disease (T / featured since 26 March 2007), Colorectal cancer, Constipation, Contrast-induced nephropathy (T), ...
Refractory chemotherapy-induced nausea and vomiting; anorexia; neuropathic pain.. Dizziness, euphoria, paranoia, somnolence, ... For systemic use haematological side effects such as aplastic anaemia; agranulocytosis; leucopenia; neutropenia; etc. ... "Evidence on the use of paracetamol in febrile children". Bulletin of the World Health Organization. 81 (5): 367-72. PMC ... Pain; anaesthesia supplement; opioid-induced pruritus.. As per codeine. Respiratory depression is subject to ceiling effect. ...
Refractory chemotherapy-induced nausea and vomiting; anorexia; neuropathic pain.. Dizziness, euphoria, paranoia, somnolence, ... For systemic use haematological side effects such as aplastic anaemia; agranulocytosis; leucopenia; neutropenia; etc. ... "Evidence on the use of paracetamol in febrile children". Bulletin of the World Health Organization. 81 (5): 367-72. PMC ... Opioid-induced hyperalgesia is when exposure to opioids increases the sensation of pain (hyperalgesia) and can even make non- ...
Refractory chemotherapy-induced nausea and vomiting; anorexia; neuropathic pain.. Dizziness, euphoria, paranoia, somnolence, ... For systemic use haematological side effects such as aplastic anaemia; agranulocytosis; leucopenia; neutropenia; etc. ... "Evidence on the use of paracetamol in febrile children". Bulletin of the World Health Organization. 81 (5): 367-72. PMC ... Pain; anaesthesia supplement; opioid-induced pruritus.. As per codeine. Respiratory depression is subject to ceiling effect. ...
Home , November 2015 - Volume 26 - Issue 10 , Chemotherapy-induced neutropenia and febrile neutropenia in... , Image Gallery ... Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy Anti-Cancer Drugs26(10):1054- ...
Colony-stimulating factor therapy and febrile neutropenia induced by chemotherapy: need for economical studies. T Urban, B ... Colony-stimulating factor therapy and febrile neutropenia induced by chemotherapy: need for economical studies ... Colony-stimulating factor therapy and febrile neutropenia induced by chemotherapy: need for economical studies ... Colony-stimulating factor therapy and febrile neutropenia induced by chemotherapy: need for economical studies ...
Healthcare claims databases have been used in several studies to characterize the risk and burden of chemotherapy-induced ... febrile neutropenia (FN) and effectiveness of colony-stimulating factors against FN. The accuracy of methods previously used to ... Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases. ... databases have been used in several studies to characterize the risk and burden of chemotherapy-induced febrile neutropenia (FN ...
Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J ... Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases. BMC ... Real-World Impact of a Decision Support Tool on Colony-Stimulating Factor Use and Chemotherapy-Induced Febrile Neutropenia ... Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. . J ...
Outcomes in 102 patients that present to the emergency department with chemotherapy-induced febrile neutropenia. Joo Han Lim1, ... Outcomes in 102 patients that present to the emergency department with chemotherapy-induced febrile neutropenia. Turk J Hematol ... OBJECTIVE: Febrile neutropenia (FN) is a major toxic responseto chemotherapy requiring prompt medical attention. There are a ... Keywords: Neutropenia, fever, emergency department, chemotherapy. Joo Han Lim, Hoon Kim, Woong Gil Choi, Kyung Hwan Kim, Dong ...
... discusses research on the benefits of pegfilgrastim over filgrastim in managing chemotherapy-induced febrile neutropenia (FN), ... in addition to showing a reduction in febrile neutropenia compared to patients treated with filgrastim for 5 or 11 days). He ... Dr Aapro explains how a single injection of long-acting pegfilgrastim given 24 hours after chemotherapy is sufficient, ... com/videoEmbed/advantages-of-pegfilgrastim-over-filgrastim-in-managing-chemotherapy-induced-febrile-neutropenia frameborder=0 ...
... On-line free medical diagnosis assistant. Ranked list of possible diseases from ... "Chemotherapy-Induced Febrile Neutropenia"Drugs, active principles and "Chemotherapy-Induced Febrile Neutropenia"Medicinal ... Chemotherapy-Induced Febrile Neutropenia. fever accompanied by a significant reduction in NEUTROPHIL count associated with ...
Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis ... and that such patients have a higher risk of febrile neutropenia hospitalization (FNH). Little is known about the number and ... Study population comprised adults who received a chemotherapy course with a high-risk regimen, or an intermediate-risk regimen ... CONCLUSIONS: In this retrospective evaluation, one-half of FNH episodes, outcomes, and costs among cancer chemotherapy patients ...
Expert opinion: Chemotherapy-induced febrile neutropenia and its complications are still a major health-care concern, and the ... Expert opinion: Chemotherapy-induced febrile neutropenia and its complications are still a major health-care concern, and the ... Expert opinion: Chemotherapy-induced febrile neutropenia and its complications are still a major health-care concern, and the ... Expert opinion: Chemotherapy-induced febrile neutropenia and its complications are still a major health-care concern, and the ...
Corticosteroids, IV antibiotics increase risk for chemotherapy-induced febrile neutropenia Healio. Use of corticosteroids, ... and antibiotics all appeared to increase risk for chemotherapy-induced febrile neutropenia … ...
Fermented Wheat Germ Extract Reduces Chemotherapy-Induced Febrile Neutropenia in Pediatric Cancer Patients * ... drugs and the continued administration of MSC on its own help to reduce the incidence of treatment-related febrile neutropenia ... of anticancer therapies with the medical nutriment MSC helps to reduce the incidence of treatment-related febrile neutropenia ... 30 febrile neutropenic episodes (24.8%) in the MSC group versus 46 (43.4%) in the control group (Wilcoxon signed rank test, P ...
Key Benefits of Chemotherapy Induced Febrile Neutropenia Market Report. Chemotherapy Induced Febrile Neutropenia market report ... Chemotherapy Induced Febrile Neutropenia Drugs Uptake and Key Market Players. The Chemotherapy Induced Febrile Neutropenia ... 4. Chemotherapy Induced Febrile Neutropenia Market Overview at a Glance. 5. Chemotherapy Induced Febrile Neutropenia Disease ... Chemotherapy Induced Febrile Neutropenia Market. The Chemotherapy Induced Febrile Neutropenia market outlook section of the ...
Delayed antibiotic administration in patients with febrile neutropenia may result in adverse outcomes. Febrile neutropenia (FN ... was to determine and analyze retrospectively the number of patients admitted with chemotherapy induced febrile neutropenia and ... Results: A total of 459 patients starting chemotherapy were analyzed. 10 patients were admitted with postchemotherapy febrile ... administration of antibiotics within one hour of admission is imperative for patients with cancer who have febrile neutropenia ...
BACKGROUND: Chemotherapy-induced febrile neutropenia is a medical emergency complicating the treatment of many cancer patients ... METHODS: A prospective study of all cases of chemotherapy-induced febrile neutropenia in the South West London Cancer Network ... A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of ... A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of ...
title = "Antimicrobial agent prescription patterns for chemotherapy-induced febrile neutropenia in patients with hematological ... T1 - Antimicrobial agent prescription patterns for chemotherapy-induced febrile neutropenia in patients with hematological ... Antimicrobial agent prescription patterns for chemotherapy-induced febrile neutropenia in patients with hematological ... Antimicrobial agent prescription patterns for chemotherapy-induced febrile neutropenia in patients with hematological ...
Healthcare claims databases have been used in several studies to characterize the risk and burden of chemotherapy-induced ... febrile neutropenia (FN) and effectiveness of colony-stimulating factors against FN. The accuracy of methods previously used to ... From: Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases ... FN Patients: neutropenia, any position (n=71) FN Patients: Neutropenia + Fever,Any Position (n=28) FN Patients: neutropenia or ...
BACKGROUND: Risk models of chemotherapy-induced (CIN) and febrile neutropenia (FN) have to date focused on determinants ... History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF ... Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer ... Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim ( ...
Antimicrobial agent prescription patterns for chemotherapy-induced febrile neutropenia in Antimicrobial agent prescription ... Approximately, 69% of the febrile neutropenia episodes had severe neutropenia. The duration of neutropenia was less than 1 week ... patterns for chemotherapy-induced febrile neutropenia in patients with hematological malignancies at Sultan Qaboos University ... describe the antimicrobial prescription patterns of patients with hematological malignancies who developed febrile neutropenia ...
401 experienced a total of 458 febrile neutropeniaepisodes. Risk of febrile neutropenia during the chemotherapy regimen course ... Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. J ... Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. J ... Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. J ...
Weycker D, Hanau A, Lonshteyn A, Bowers C, Bensink M, Garawin T, Chandler D. Risk of chemotherapy-induced febrile neutropenia ... Weycker D, Hanau A, Lonshteyn A, Bowers C, Bensink M, Garawin T, Chandler D. Risk of chemotherapy-induced febrile neutropenia ... Weycker D, Hanau A, Lonshteyn A, Bowers C, Bensink M, Garawin T, Chandler D. Risk of chemotherapy-induced febrile neutropenia ... BACKGROUND: Two recent evaluations reported that risk of febrile neutropenia (FN) may be higher when pegfilgrastim prophylaxis ...
... are indicated for prophylaxis or management of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN). Guidelines ... Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day ... RESULTS: A total of 5930 chemotherapy cycles from 1423 evaluable patients from MONITOR-GCSF had data for day of G-CSF ... Endotoxin-induced immunotolerance is associated with loss of monocyte metabolic plasticity and reduction of oxidative burst. ...
We created a prediction model for febrile neutropenia with first cycle of chemotherapy in a large population of elderly ... or neutropenia occurring after chemotherapy initiation for patients with breast, colorectal, prostate, and lung cancer. In ... receipt of myelosuppressive chemotherapy (1.11; 95% CI: 0.94-1.32), and receipt of chemotherapy within 1 month of diagnosis [1 ... when febrile neutropenia (FN) risk is greater than 20%. Advanced age is a risk factor for FN; however, little is known about ...
Fermented wheat germ extract reduces chemotherapy-induced febrile neutropenia in pediatric patients.Oct 01, 2004. ... Avemar and Echinacea extracts can effectively induce mobilization and homing of CD34+ stem cells to the myocardial tissue and ...
Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. ... Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian ... Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses ... Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. ...
Clinical Characteristics That Increase Risk of Chemotherapy-Induced Febrile Neutropenia Identified By Tiffany Garbutt, PhD ... Pegteograstim may be effective for reducing chemotherapy-induced neutropenia Publish Date October 1, 2015 ... various cancers to identify clinical factors that contribute to the risk of developing chemotherapy-induced febrile neutropenia ... Pegteograstim is as effective as pegfilgrastim in reducing chemotherapy-induced neutropenia in patients with breast cancer. ...
1 search for keyword(s) Chemotherapy-Induced Febrile Neutropenia Add the result to your basket Refine your search Generate ... Cervicofacial necrotizing fasciitis of odontogenic origin following chemotherapy: a case report and implications for oral care ...
Chemotherapy-induced febrile neutropenia in patients with breast cancer. A multivariate risk assessment model for first cycle ... The promising effect of linagliptin and/or indole-3-carbinol on experimentally-induced polycystic ovarian syndrome. ... Assessment of physicians knowledge and attitudes in the management of febrile seizures. ...
Critical appraisal of biosimilar filgrastim (Nivestim™) for febrile and chemotherapy-induced neutropenia Waller CF ...
Industry Research on Febrile Neutropenia Global Clinical Trials Review, H2, 2017 of 114 pages is now available with ... Chemotherapy Induced Anemia Global Clinical Trials Review, H2, 2018. Chemotherapy Induced Anemia Global Clinical Trials Review ... "Febrile Neutropenia Global Clinical Trials Review, H2, 2017" provides an overview of Febrile Neutropenia clinical trials ... "Chemotherapy Induced Anemia Global Clinical Trials Review, H2, 2018" provides an overview of Chemotherapy Induced Anemia ...
H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia ... ... Febrile Neutropenia Global Clinical Trials ... $ 2500 December 2019 Prostate Specific Antigen - Pipeline Revie ... $ 3500 ... provides an overview of the Chemotherapy Induced Neutropenia (Toxicology) pipeline landscape.. Chemotherapy-induced neutropenia ... Chemotherapy Induced Neutropenia (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market ...
  • 1.0×10 9 /L, and body temperature ≥38.3°C or receipt of antibiotics) and claims-based definition (diagnosis codes for neutropenia, fever, and/or infection). (biomedcentral.com)
  • Neutropenia both increases the risk of infection and diminishes patients' ability to fight infection. (biomedcentral.com)
  • This common and well-studied complication of neutropenia is called febrile neutropenia (FN), regardless of whether infection is ultimately documented as the cause of fever. (biomedcentral.com)
  • Because the study databases did not include information on absolute neutrophil count (ANC) and body temperature, and because there is no specific diagnosis code for FN, various combinations of codes for neutropenia, fever, and/or infection were utilized to identify FN in these studies. (biomedcentral.com)
  • Background: Curative intent chemotherapy for acute myelogenous leukemia (AML) leads to prolonged severe neutropenia, during which patients are highly susceptible to infection. (ebscohost.com)
  • Determines if filgrastim used in addition to standard inpatient antibiotic therapy accelerated recovery from infection associated with chemotherapy-induced neutropenia. (ebscohost.com)
  • These compounds are used frequently by oncologists to reduce the nadir of chemotherapy-induced neutropenia or hasten the recovery of normal neutrophil counts after chemotherapy in the hope that infection will not develop or that febrile neutropenia will quickly resolve. (annals.org)
  • Infection is the major consequence of neutropenia. (annals.org)
  • We believe that knowing the periods of severe neutropenia development and intensification of neutropenic episodes could be important in reducing infection-related losses. (scirp.org)
  • Baulking and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem stall relocate recipients in the cycle of newer broad-spectrum antifungal agents and diagnostic adjuncts. (nippon-kan.org)
  • The risk of bacterial infection is related to the severity and duration of neutropenia. (online-vitamins-guide.com)
  • Because neutropenia itself has no specific symptoms, it is usually diagnosed when an infection occurs. (online-vitamins-guide.com)
  • Neutropenia is a potentially serious side effect of chemotherapy and a major risk factor for infection, which can be life-threatening. (tripdatabase.com)
  • This review is an update of a previously published Cochrane review.The primary objective of this review was to determine the efficacy of an LBD versus a control diet in preventing infection and in decreasing (infection-related) mortality in adult and paediatric cancer patients receiving chemotherapy that causes episodes of neutropenia . (tripdatabase.com)
  • The most serious complication of neutropenia is infection, which can be fatal. (tripdatabase.com)
  • Neulasta was approved for use by the U.S. Food and Drug Administration (FDA) for people at risk of infection while undergoing chemotherapy or radiation therapy . (verywellhealth.com)
  • It is not given to everyone on chemotherapy but mainly those whose drug regimens are associated with a 17% or greater risk of febrile neutropenia (characterized by fever and other signs of infection). (verywellhealth.com)
  • Thirty percent of patients surveyed experienced an infection as a result of chemotherapy, 45 percent of which were associated with neutropenia or febrile neutropenia according to findings from a pan-European patient and nurse survey presented today at the 7th Annual European Oncology Nursing Society Spring Convention. (news-medical.net)
  • Amgen Inc. (Nasdaq:AMGN), the world's largest biotechnology company, today announced data from a Phase 3 study showing that administration of Neulasta(R) (pegfilgrastim) in the first and subsequent cycles of chemotherapy significantly lowers the rate of infection, as manifested by febrile neutropenia (low white blood cell count with fever), hospitalization and the use of intravenous anti-infectives in breast cancer patients receiving moderately myelosuppressive (strong) chemotherapy. (amgen.com)
  • 4 Congenital or acquired forms of neutropenia are associated with the highest risks of bacterial and fungal infection, 5 indicating a strong evolutionary pressure to maintain granulopoiesis at high levels and sustain a large mobilizable pool of PMNs in the BM. (bloodjournal.org)
  • Aim: Management of febrile neutropenia is challenged by lacking microbiological and clinical documentation of infection. (scirp.org)
  • We aimed to undertake a systematic review evaluating the diagnostic accuracy of procalcitonin as a marker of infection in febrile neutropenia. (scirp.org)
  • PCT has been studied in immunocompromized patients with sepsis, first by Al-Nawas in 1996 [9] studying 55 patients with various causes of immunosuppression, e.g. hematological malignancies, chemotherapy induced neutropenia, HIV infection and following organ transplantation. (scirp.org)
  • A common and potentially life-threatening complication of the treatment of childhood cancer is infection, which frequently presents as fever with neutropenia. (biomedcentral.com)
  • There remain many episodes of febrile neutropenia (FNP), possibly two-thirds or more, among patients in whom no significant infection is identified and in whom this aggressive management strategy is likely to be excessive [ 7 ]. (biomedcentral.com)
  • Ziextenzo is indicated to decrease the incidence of infection, as manifested by febrile neutropenia (low white blood cell count with a fever), in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. (sandoz.com)
  • When a cancer patient with febrile neutropenia gets an infection, it can have serious consequences such as delays or dose reductions of chemotherapy," said Carol Lynch, President of Sandoz Inc. "The approval of Ziextenzo expands our oncology portfolio, providing physicians with a long-acting supportive oncology biosimilar option. (sandoz.com)
  • A study has shown that each year in the US, more than 60,000 cancer patients are hospitalized with evidence of neutropenia, including fever or infection, with more than 4,000 deaths as a result. (sandoz.com)
  • Sandoz is seeking approval for use of biosimilar pegfilgrastim in the same indication as the reference medicine, for the prevention of chemotherapy-induced infection, known as febrile neutropenia, which includes fever brought on by low neutrophils (a specific type of white blood cells). (ecmconnection.com)
  • The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. (qxmd.com)
  • Granulocyte colony-stimulating factors (G-CSFs) are indicated for prophylaxis or management of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN). (qxmd.com)
  • Douglas AG, Schwab P, Lane D, Kennedy K, Slabaugh SL, Bowe A. A comparison of brand and biosimilar granulocyte-colony stimulating factors for prophylaxis of chemotherapy-induced febrile neutropenia. (ajmc.com)
  • The introduction of granulocyte colony-stimulating factors (G-CSFs) in clinical practice has remarkably reduced the duration and severity of neutropenia, as well as the incidence of FN, thus allowing the administration of chemotherapeutic agents at the optimal dose and time with lower risk. (dovepress.com)
  • Mitchell S, Li X, Woods M, Garcia J, Hebard-Massey K, Barron R, Samuel M (2016) Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: a systematic review. (springer.com)
  • Wang L, Baser O, Kutikova L, Page JH, Barron R (2015) The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. (springer.com)
  • Matti Aapro, MD, from the Clinique de Genolier, Genolier, Switzerland discusses research on the benefits of pegfilgrastim over filgrastim in managing chemotherapy-induced febrile neutropenia (FN), which he presented at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. (oncologytube.com)
  • Dr Aapro explains how a single injection of long-acting pegfilgrastim given 24 hours after chemotherapy is sufficient, in addition to showing a reduction in febrile neutropenia compared to patients treated with filgrastim for 5 or 11 days). (oncologytube.com)
  • Areas covered: The purpose of this article is to review the physiopathology of chemotherapy-induced febrile neutropenia and its consequences, and the current evidence regarding the pharmacological properties, clinical efficacy and cost-effectiveness of pegfilgrastim as a strategy to prevent chemotherapy-induced febrile neutropenia in patients with solid tumors. (elsevier.com)
  • For patients at higher risk of failure with daily G-CSF prophylaxis (e.g. risk of non-compliance, difficulties on performing regular hemograms, high risk of developing febrile neutropenia), pegfilgrastim might be the most appropriate option. (elsevier.com)
  • Weycker D, Hanau A, Lonshteyn A, Bowers C, Bensink M, Garawin T, Chandler D. Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged ≥65 years: a retrospective evaluation using Medicare claims. (pai2.com)
  • BACKGROUND: Two recent evaluations reported that risk of febrile neutropenia (FN) may be higher when pegfilgrastim prophylaxis (PP) is administered on same day as chemotherapy rather than per recommendation (1-3 days following chemotherapy). (pai2.com)
  • In a comparison study, the Onpro® device was found to be a safe and effective alternative to manual injection of pegfilgrastim in patients receiving chemotherapy. (oncologynurseadvisor.com)
  • The risk of second-cycle febrile neutropenia was significantly higher among patients who discontinued pegfilgrastim after the first cycle. (oncologynurseadvisor.com)
  • Pegteograstim is as effective as pegfilgrastim in reducing chemotherapy-induced neutropenia in patients with breast cancer. (oncologynurseadvisor.com)
  • Lipegfilgrastim is a glycopegylated G-CSF, alternative to pegfilgrastim, and has shown in randomized trials, to be equivalent to pegfilgrastim in reducing the incidence of severe neutropenia and FN in patients with breast cancer receiving chemotherapy, with a similar safety profile. (dovepress.com)
  • Colony-stimulating factors such as filgrastim and pegfilgrastim can reduce the incidence of neutropenia, but the clinic visits for these treatments can disrupt patients' routines and activities. (biomedcentral.com)
  • The mean amounts of time affected by these visits ranged from approximately 109 hours (hospitalization for neutropenia) and 8 hours (physician and chemotherapy) to less than 3 hours (laboratory and treatment with filgrastim or pegfilgrastim). (biomedcentral.com)
  • The visits for filgrastim or pegfilgrastim were comparable in length, but treatment with filgrastim requires several visits per chemotherapy cycle and treatment with pegfilgrastim requires only 1 visit. (biomedcentral.com)
  • Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. (arizona.edu)
  • Patients receiving pegfilgrastim (Neulasta®) for the treatment of neutropenia can experience bone pain following the injections required to achieve effective neutrophil levels. (springer.com)
  • ANF-RHO had unique, prolonged PK/PD attributes as compared to marketed pegfilgrastim, suggesting that it may provide an improved clinical benefit in further clinical studies in patients with chemotherapy-induced or chronic idiopathic neutropenia. (springer.com)
  • Brugger W, Bacon P, Lawrinson S, Romieu G (2009) Neutrophil recovery in elderly breast cancer patients receiving adjuvant anthracycline-containing chemotherapy with pegfilgrastim support. (springer.com)
  • Kirshner JJ, Heckler CE, Janelsins MC, Dakhil SR, Hopkins JO, Coles C, Morrow GR (2012) Prevention of Pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the University of Rochester Cancer Center Clinical Community Oncology Program Research Base. (springer.com)
  • Pegfilgrastim is safe and effective in supporting neutrophil recovery and reducing febrile neutropenia after conventional chemotherapy. (springer.com)
  • This study found no evidence that the use of pegfilgrastim is associated with greater cost in lymphoma and myeloma patients after high-dose chemotherapy and PBSC transplantation. (springer.com)
  • Failures may increase the risk of chemotherapy-induced febrile neutropenia (FN) and FN-related hospitalizations (FN-HOSP) beyond the FN and FN-HOSP rates for prophylaxis with single-injection pegfilgrastim (PEG) or daily injections of reference (REF-FIL) or Sandoz filgrastim biosimilar (BIOSIM-FIL). (confex.com)
  • While pegfilgrastim is a proven effective and safe treatment for febrile neutropenia-related infections, many cancer patients throughout Europe are not treated with this medicine. (ecmconnection.com)
  • For the claims-based definition including diagnosis codes for neutropenia plus fever in any position (n=28), PPV was 100% and sensitivity was 34% (95% CI: 24-45). (biomedcentral.com)
  • Patients hospitalized for chemotherapy-induced FN can be identified in healthcare claims databases--with an acceptable level of mis-classification--using diagnosis codes for neutropenia, or neutropenia plus fever. (biomedcentral.com)
  • fever accompanied by a significant reduction in NEUTROPHIL count associated with CHEMOTHERAPY. (lookfordiagnosis.com)
  • Approach to fever assessment in ambulatory cancer patients receiving chemotherapy: a clinical practice guideline. (semanticscholar.org)
  • We evaluated pentraxin 3 as a marker for complications of neutropenic fever in 100 hematologic patients receiving intensive chemotherapy. (haematologica.org)
  • Sometimes daily buy norvasc 10mg line , said discount 100mg geriforte fast delivery , outpatient quinolone monotherapy with a view low-risk cancer patients with fever and neutropenia: a captain swot of 40 patients based on validated risk-prediction rules buy zanaflex 2mg otc . (nippon-kan.org)
  • Voriconazole compared with liposomal amphotericin B for the sake of experimental antifungal cure in patients with neutropenia and continuing fever. (nippon-kan.org)
  • A 12 year old boy, suffering from acute lymphoid leukemia (ALL) on Berlin-Frankfurt-Muenster (BFM) high-risk protocol had fever up to 101-102 °F along with neutropenia [absolute neutrophil count (ANC): 300 cells/cumm]. (pediatriconcall.com)
  • 1) If children with acute myeloid leukemia (AML) receiving highly myelosuppressive chemotherapy have prolonged neutropenia and persistent fever despite prolonged (≥ 96 hours) use of broad-spectrum antibiotic therapy, then, they are considered high-risk candidates for invasive fungal disease and should receive empirical antifungal therapy. (pediatriconcall.com)
  • If, despite antifungal therapy, there is persistent fever and neutropenia then search for a definitive etiological agent along with deep tissue involvement should be done. (pediatriconcall.com)
  • In acute neutropenia, a person can develop fever and painful sores (ulcers) around the mouth and anus. (online-vitamins-guide.com)
  • Due to an inability to mount an inflammatory response, many patients with febrile neutropenia do not demonstrate localising signs or symptoms other than fever. (tripdatabase.com)
  • BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Febrile neutropenia Last reviewed: February 2019 Last updated: October 2018 Summary Defined as a fever >38°C (>101°F) for 1 hour, with an absolute neutrophil count (ANC) of ≤500 cells/microlitre, or an ANC ≤1000 cells/microlitre with a projected nadir of ≤500 cells/microlitre. (tripdatabase.com)
  • It is similar to a natural protein (granulocyte-colony stimulating factor) produced by a person's own body, and may be used to reduce the duration of neutropenia (low white blood cell count) and the occurrence of febrile neutropenia (low white blood cell count with a fever). (ecmconnection.com)
  • Neutropenia is a common side effect of myelosuppressive chemotherapy. (biomedcentral.com)
  • The study population included adult patients who received myelosuppressive chemotherapy for a solid tumor or non-Hodgkin's lymphoma. (pai2.com)
  • Febrile neutropenia remains a common occurrence among patients receiving myelosuppressive chemotherapy and typically results in extended hospitalization and, for many patients, death. (pai2.com)
  • Neutropenia and febrile neutropenia (FN) are frequent and potentially fatal toxicities of myelosuppressive anticancer treatments. (dovepress.com)
  • Furthermore, lipegfilgrastim was more effective than the placebo in reducing the incidence of severe neutropenia, its duration, and time to absolute neutrophil count recovery, in patients with non-small cell lung cancer receiving myelosuppressive therapy. (dovepress.com)
  • Neutropenia, the most common dose-limiting toxicity of myelosuppressive chemotherapy, has substantial clinical and economic consequences. (biomedcentral.com)
  • Neulasta is used to decrease the risk of neutropenia (a low neutrophil count) in adults or children undergoing myelosuppressive (bone-marrow-suppressing) chemotherapy. (verywellhealth.com)
  • Use of the recombinant human granulocyte colony-stimulating factor (rhG-CSF) filgrastim accelerates neutrophil recovery following myelosuppressive chemotherapy. (springer.com)
  • This study provides compelling evidence that administering Neulasta in the first and subsequent cycles of moderately myelosuppressive chemotherapy can significantly reduce the risk of potentially life-threatening infections that can result in hospitalizations and require IV antibiotics," said Schwartzberg. (amgen.com)
  • INTRODUCTION: Evidence suggests that many cancer chemotherapy patients who are candidates for colony-stimulating factor (CSF) prophylaxis do not receive it or receive it inconsistent with guidelines, and that such patients have a higher risk of febrile neutropenia hospitalization (FNH). (fredhutch.org)
  • Outcomes included occurrence of CIN of any grade (CIN1/4), grade 3 or 4 (CIN3/4), grade 4 (CIN4), or FN: CIN/FN-related hospitalization or CIN/FN-related chemotherapy disturbance. (qxmd.com)
  • Primary prophylaxis with granulocyte colony-stimulating factor provided only a low-to-modest benefit in reducing neutropenia-related hospitalization in patients with breast cancer receiving low-to-intermediate risk chemotherapy regimens. (oncologynurseadvisor.com)
  • A study published in the Journal of Managed Care & Specialty Pharmacy found that filgrastim and filgrastim-sndz were noninferior for the prevention of febrile neutropenia events that would require hospitalization. (ajmc.com)
  • There are no significant differences between filgrastim and its biosimilar filgrastim-sndz in the prevention of febrile neutropenia events that require hospitalization, according to a study published in the Journal of Managed Care & Specialty Pharmacy . (ajmc.com)
  • The amount of patients with a febrile neutropenia outcome that required hospitalization and the amount of patients that experienced a potential serious adverse event after G-CSF use were observed in the 14 days following the index date. (ajmc.com)
  • When comparing filgrastim and filgrastim-sndz, noninferiority was determined based on both the broad and narrow definitions for febrile neutropenia requiring hospitalization, with -0.6% (90% CI, -5.1%-4.0%, P = .84) and -0.8% (90% CI, -3.8%-2.1%, P = .64) incidence differences, respectively. (ajmc.com)
  • Overall, results showed that while filgrastim and filgrastim-sndz were noninferior for the prevention of febrile neutropenia events that would require hospitalization, inferiority could not be established for serious adverse events. (ajmc.com)
  • Chemotherapy-induced febrile neutropenia (FN) predisposes patients to life-threatening infections and typically requires hospitalization. (cancernetwork.com)
  • Treatment of febrile neutropenic patients with cancer who require hospitalization: a incipient randomized office comparing imipenem and cefepime purchase discount voveran on line spasms 1983. (nippon-kan.org)
  • Data from the randomized, double-blind, placebo-controlled study of 928 patients show that first and subsequent-cycle administration of Neulasta resulted in a 94 percent reduction in the incidence of febrile neutropenia, a 93 percent reduction in the incidence of hospitalization and an 80 percent reduction in the incidence of intravenous anti-infective use in patients previously considered at moderate risk for neutropenic complications. (amgen.com)
  • 21 The decision to administer CSF is relatively straightforward for patients receiving chemotherapy regimens with a high risk of inducing FN. (jnccn.org)
  • Certain chemotherapy regimens and chemotherapy doses are more likely to cause neutropenia. (saurashtranews.com)
  • Docetaxel-based chemotherapy regimens have substantially improved survival and recurrence rates for cancer patients. (hindawi.com)
  • Safety profile of docetaxel regimens includes toxicities, particularly a high risk of neutropenia and febrile neutropenia. (hindawi.com)
  • Improved outcomes have largely been achieved by more intensive and toxic treatment regimens, including cytotoxic chemotherapy, radiotherapy and / or surgery. (journals.co.za)
  • All chemotherapy for patients with advanced cancers was adopted from regimens suggested by NCCN guidelines. (koreascience.or.kr)
  • Purpose: An open-label, matched-pair (by diagnosis, stage of disease, age, and gender) pilot clinical trial was conducted to test whether the combined administration of the medical nutriment MSC (Avemar) with cytotoxic drugs and the continued administration of MSC on its own help to reduce the incidence of treatment-related febrile neutropenia in children with solid cancers compared with the same treatments without MSC. (drcalapai.net)
  • Anemia and thrombocytopenia frequently occur as a side effect of cytotoxic chemotherapy and blood product transfusions are needed during treatment. (scirp.org)
  • Bowen, J. 2018-05-29 00:00:00 Despite significant advances in our ability to treat cancer, cytotoxic chemotherapy continues to be the mainstay treatment for many solid tumours. (deepdyve.com)
  • Granulocyte colony-stimulating factor (G-CSF) is often used in cancer patients receiving cytotoxic drugs to prevent or reduce high grade neutropenia. (springer.com)
  • 60 receiving cytotoxic chemotherapy who have consented to DNA extraction and analysis for CHIP. (clinicaltrials.gov)
  • Furthermore, lenograstim may increase the patient's exposure to chemotherapy allowing patients to receive optimal dosing and duration of treatment, benefitting survival. (hindawi.com)
  • Deep neutropenia duration was 36.6 ± 12.7 (18-68) days during the induction. (scirp.org)
  • There was a positive correlation between the number of FEN episodes and duration of neutropenia. (scirp.org)
  • In this trial, we investigated the level of severe neutropenia, anemia, thrombocytopenia incidence, deep neutropenia duration, incidence of febrile neutropenic episodes, and the extent of transfusion during intense chemotherapy in leukemic children, treated with ALL IC-BFM 2009 protocol. (scirp.org)
  • OBJECTIVES: I. Determine the efficacy of recombinant keratinocyte growth factor in reducing the duration of severe oral mucositis induced by total body irradiation and high dose chemotherapy in patients with hematologic malignancies. (knowcancer.com)
  • Determine the incidence and duration of severe oral mucositis, grade 2-4 diarrhea, and febrile neutropenia in these patients. (knowcancer.com)
  • Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind, randomized, placebo-controlled study. (koreascience.or.kr)
  • Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF: results of a prospective randomised trial. (koreascience.or.kr)
  • Our aim in using this model is to define a group of individuals at low risk for febrile neutropenia who might be treated with reduced intensity or duration of antibiotic therapy and so reduce the inconvenience and cost of these episodes, as well as to define a group of patients at very high risk of complications who could be subject to more intensive therapies. (biomedcentral.com)
  • Static patient-level risk models of 'ever' experiencing CIN/FN adverse events and consequences during a planned chemotherapy regimen included predictors related to history, risk factors, and prophylaxis initiation and intensity. (qxmd.com)
  • For each patient, each chemotherapy regimen course and each cycle within each regimen course was characterized. (pai2.com)
  • Risk of febrile neutropenia during the chemotherapy regimen course was 16.8% (95% CI: 15.3, 18.4). (pai2.com)
  • Taxotere-cyclophosphamide (TC) chemotherapy is commonly used as an adjuvant chemotherapy regimen in patients with resected early stage breast cancer. (centerwatch.com)
  • Granotax was a prospective, open label, multicentre, national phase IV study that evaluated the incidence and severity of neutropenia in adult patients with solid tumors being treated with a docetaxel-based regimen while receiving the GCSF lenograstim. (hindawi.com)
  • The low incidence of adverse effects and chemotherapy dose changes, delays, and withdrawals supports the use of lenograstim as effective primary prophylaxis in South African patients being treated with a docetaxel-based regimen. (hindawi.com)
  • Both guidelines from NCCN and ASCO recommend using colony-stimulating factors (CSF) for patients with lung cancer whose chemotherapy regimen carries greater than a 20% risk of developing febrile neutropenia. (ajmc.com)
  • Beginning in October 2004, oncology nurses applied the new risk assessment tool to all patients initiating chemotherapy or a new regimen. (cancernetwork.com)
  • If validated, integration of genetic factors with clinical and molecular characteristics could be used for a composite algorithm to predict risk of neutropenia prior to treatment and to facilitate clinical decision making on regimen and dosing selection of chemotherapy, as well as CSF support. (aacrjournals.org)
  • Of patients treated with ZYBRESTAT and chemotherapy, 48% were alive at six months, compared with 37% percent of patients treated with the control arm regimen. (thestreet.com)
  • Risk assessment for use of G-CSFs includes (not an all-inclusive list) disease type, chemotherapy regimen (high-dose, dose-dense, or standard-dose), risk factors, and treatment intent (curative/adjuvant vs. palliative). (bcbsnd.com)
  • Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor. (fredhutch.org)
  • Expert opinion: Chemotherapy-induced febrile neutropenia and its complications are still a major health-care concern, and the inappropriate employment of G-CSFs in clinical practice can partially explain its burden. (elsevier.com)
  • The report provides a detailed assessment of the Chemotherapy Induced Febrile Neutropenia market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors. (saurashtranews.com)
  • CONCLUSIONS: Among Medicare patients receiving chemotherapy and PP in US clinical practice, PP was administered before the recommended timing in 5% of cycles and FN incidence was significantly higher in these cycles. (pai2.com)
  • GlobalData's clinical trial report, "Febrile Neutropenia Global Clinical Trials Review, H2, 2017" provides an overview of Febrile Neutropenia clinical trials scenario. (sandlerresearch.org)
  • This report provides top line data relating to the clinical trials on Febrile Neutropenia. (sandlerresearch.org)
  • Researchers analyzed data from more than 15,000 patients in Southern California with various cancers to identify clinical factors that contribute to the risk of developing chemotherapy-induced febrile neutropenia. (oncologynurseadvisor.com)
  • A recent abstract presented at the American Society of Clinical Oncology (ASCO) annual meeting compared 2 risk models for patients with intermediate chemotherapy-induced neutropenia (CIN) risk and compared them to guidelines from ASCO and the National Comprehensive Cancer Network to determine when colony-stimulating factor should be ideally used to prevent CIN. (ajmc.com)
  • Compliance with a key pathway on the side of the command of febrile neutropenia and crashing on clinical outcomes. (nippon-kan.org)
  • In the context of a clinical trial of cyclophosphamide-containing chemotherapy for breast cancer, there were significant associations between germline GSTP1 variants and reduced risk of acute neutropenia and leucopenia after treatment. (aacrjournals.org)
  • Therefore, there is no indication for upfront chemotherapy delay from start of ADT unless clinical factors warrant a delay in starting chemotherapy. (urotoday.com)
  • The early identification of such clinical predictors enables clinicians to prevent or reduce the occurrence of adverse drug reactions in cancer patients undergoing chemotherapy through appropriate management strategies. (igi-global.com)
  • In our clinical practice, we identified several patients who developed neutropenia while receiving ceftaroline therapy. (asm.org)
  • Although transfusions of donor neutrophils are a logical solution to neutropenia, this approach has not gained clinical traction, primarily due to challenges associated with obtaining sufficiently large numbers of neutrophils from donors whilst logistically managing their extremely short shelf-life. (frontiersin.org)
  • CONCLUSIONS: In this retrospective evaluation, one-half of FNH episodes, outcomes, and costs among cancer chemotherapy patients who were candidates for CSF prophylaxis occurred in those who either did not receive it or received it inconsistent with guidelines. (fredhutch.org)
  • RESULTS AND CONCLUSION: Our results reflect those of the recent National Chemotherapy Advisory Group (NCEPOD, 2008)/National Confidential Enquiry into Patient Outcomes and Death reports (NCAG, 2009) and highlight the need for network-wide c inical care pathways to improve outcomes in this area, British Journal of Cancer (2011) 104, 407-412. (icr.ac.uk)
  • Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). (qxmd.com)
  • Improvements in outcomes, however, are compromised by the considerable toxicities associated with chemotherapy, the most notable being neutropenia. (centerwatch.com)
  • Overall, outcomes are favorable with approximately 80% of patients achieving durable remissions with chemotherapy ± radiotherapy. (renalandurologynews.com)
  • Pulmonary infiltrates during Chemotherapy-induced febrile Neutropenia: Incidence, patterns and outcomes. (pakmedinet.com)
  • Gascon P, Aapro M, Ludwig H, Bokemeyer C, Boccadoro M, Turner M, Denhaerynck K, MacDonald K, Abraham I (2016) Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). (springer.com)
  • Empirical antibiotic therapy upon presentation has dramatically improved outcomes and decreased mortality from febrile neutropenia . (tripdatabase.com)
  • In the IPD protocol, we will collect and synthesise IPD from multiple studies and examine the outcomes of episodes of febrile neutropenia as a consequence of their treatment for malignant disease. (biomedcentral.com)
  • Building on this success, Ziextenzo can help increase positive treatment outcomes for patients undergoing chemotherapy and drive significant savings for the healthcare system. (sandoz.com)
  • Objectives: The aim of this study was to describe the antimicrobial prescription patterns of patients with hematological malignancies who developed febrile neutropenia (FN) at Sultan Qaboos University Hospital (SQUH) in Oman. (elsevier.com)
  • 109 episodes per 1,000 patients), 41.3% (95% CI: 40.1-42.5) occurred among patients who did not receive CSF prophylaxis in that cycle, and 8.8% (8.1-9.5) occurred among those who received CSF prophylaxis on the same day as chemotherapy. (fredhutch.org)
  • Approximately, 69% of the febrile neutropenia episodes had severe neutropenia. (elsevier.com)
  • We applied predictive modeling using multivariate logistic regression to identify determinants of CIN/FN episodes and related hospitalizations and chemotherapy disturbances (CIN/FN consequences) in analyses at the patient ('ever' during the whole period of chemotherapy) and cycle-level (during a given chemotherapy cycle). (qxmd.com)
  • Febrile neutropenia episodes were categorized as inpatient or outpatient based on the initial setting of care (i.e. acute-care inpatient facility vs. ambulatory care facility). (pai2.com)
  • RESULTS: Among the 2131 patients in this study, 401 experienced a total of 458 febrile neutropenia episodes. (pai2.com)
  • Groups did not differ as to CIN1/4 and FN episodes, or CIN/FN-related hospitalizations or chemotherapy disturbances. (qxmd.com)
  • 53% of the febrile neutropenic (FEN) episodes developed during the induction period. (scirp.org)
  • Demographic features, risk groups, hemogram data obtained during treatment, number of febrile neutropenic episodes, the quantities of erythrocyte, and apheresis suspension were recorded. (scirp.org)
  • Mylan and Biocon) for prevention of febrile neutropenia. (mdedge.com)
  • Background: Despite major advances in its prevention and treatment, febrile neutropenia remains a most concerning complication of cancer chemotherapy. (mdpi.com)
  • This team demonstrated that a determined and systematic approach to assessing risk for neutropenia can be accomplished within a clinic and the complication of febrile neutropenia decreased. (cancernetwork.com)
  • Febrile neutropenia (FN) is a frequent complication following chemotherapy in hematological and oncologycal patients. (scirp.org)
  • Idiopathic Neutropenia - a rare form of neutropenia which develops in children and adults usually in response to an illness. (online-vitamins-guide.com)
  • This real-world evidence indicates that CIN/FN prophylaxis initiated with biosimilar filgrastim within 24-72 h post-chemotherapy is effective and safe. (qxmd.com)
  • Zarxio (filgrastim-sndz), a biosimilar of filgrastim, is efficient and well tolerated for the prophylaxis of chemotherapy-induced neutropenia. (oncologynurseadvisor.com)
  • 1 Sandoz is now the first and only company to offer physicians in the US the choice between a long- and short-acting biosimilar filgrastim treatment to best suit the individual needs of tens of thousands of patients undergoing chemotherapy. (sandoz.com)
  • Neutropenia is the most serious hematologic toxicity of cancer chemotherapy and it often limits the doses of chemotherapy that can be tolerated and Neutropenia complications may also lead to treatment delays, or early treatment termination, compromising disease control and the potential for cure. (saurashtranews.com)
  • In this 3-year prospective study, we compared the long PTX3 with C-reactive protein as a biomarker in predicting complications (bacteremia and septic shock) among 100 hematologic patients with febrile neutropenia after intensive chemotherapy. (haematologica.org)
  • Both of these agents are effective in reducing the risks and incidence of neutropenia and its complications, but they too can affect patients' quality of life, by requiring additional medical visits. (biomedcentral.com)
  • This study investigates whether CHIP in lymphoma patients aged 60 years and older is a risk factor for chemotherapy-related complications like low blood counts, infections, cardiac events, hospitalizations, dose delays and dose reductions, and failure to recover normal blood counts after chemotherapy finishes. (clinicaltrials.gov)
  • The investigators want to investigate whether CHIP is also a risk factor for chemotherapy-related complications like low blood counts, infections, cardiac events, hospitalizations, dose delays and dose reductions. (clinicaltrials.gov)
  • Determine if CHIP is an independent risk factor for chemotherapy-induced complications. (clinicaltrials.gov)
  • For the prevention of chemotherapy-induced nausea and vomiting, NEPA, a novel combination of a neurokinin-1 (NK1) receptor antagonist and the 5-HT3 receptor antagonist palonosetron (Aloxi), has been s. (ascopost.com)
  • This why people undergoing chemotherapy will often experience things like hair loss, nausea, vomiting, and anemia. (verywellhealth.com)
  • Focusing on patients with cancer, this chapter describes the use of a pharmaco-cybernetics approach to identify clinically relevant predictors of two debilitating adverse drug reactions, which are a cause of patient safety - chemotherapy-induced nausea and vomiting and febrile neutropenia. (igi-global.com)
  • Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis. (semanticscholar.org)
  • Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. (semanticscholar.org)
  • Introduction: Neutropenia and febrile neutropenia are the most common and most severe bone marrow toxicities of chemotherapy. (elsevier.com)
  • infections occur mainly in patients with prolonged neutropenia, and the mortality rate can reach 90%in patients with allogenic bone marrow transplantation2. (ebscohost.com)
  • Cyclic Neutropenia - tends to occur every three weeks and lasting three to six days at a time due to changing rates of cell production by the bone marrow. (online-vitamins-guide.com)
  • Radiation induced neutropenia is related to the amount of exposure and if the site is an area carrying bone marrow (such as the sternum or skull). (online-vitamins-guide.com)
  • CHIP is also associated with the development of bone marrow cancers that occur after chemotherapy. (clinicaltrials.gov)
  • Given the increasing age of patients diagnosed with cancer as well as therapeutic interventions, the high mortality rate associated withchemotherapy-induced FN in elderly patients requires further study in order to reduce the risk of death. (tjh.com.tr)
  • Febrile neutropenia consequences included hospital length of stay and mortality ( inpatient cases only), as well as number of febrile neutropenia -related outpatient encounters. (pai2.com)
  • Febrile neutropenia-related hospitalizations still account for morbidity, and mortality among patients with breast cancer. (oncologynurseadvisor.com)
  • Chemotherapy-induced neutropenia (CIN) and febrile neutropenia carry high mortality rates, but the treatment that can be used to prevent both is expensive, so it needs to be used judiciously. (ajmc.com)
  • Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J (2010) Risk of mortality in patients with cancer who experience febrile neutropenia. (springer.com)
  • Chemotherapy-induced immuno suppression renders children who receive treatment for cancer extremely vulnerable to life-threatening infections, which are a major cause of morbidity and mortality. (journals.co.za)
  • Forty-one children (2 - 17 years old) with a diagnosis of intermediate or standard risk ALL who were treated with chemotherapy between April 2011 and June 2015 whose files were complete, were included in this study. (scirp.org)
  • Despite the recent development of chemotherapeutic agents, the median survival of CRC patients with PD treated with systemic chemotherapy is 10-16 months after diagnosis, which is much shorter than the median survival of those with other organ metastases derived from CRC ( 5 , 6 ). (spandidos-publications.com)
  • A multicenter open randomized trial was conducted to compare cefepime monotherapy with cefepime/amikacin combination (dual) therapy in treating febrile neutropenic patients with hematologic disorders. (ebscohost.com)
  • Sepsis remains an important cause of death among hematologic patients receiving intensive chemotherapy despite progress in supportive care and use of antimicrobial drugs. (haematologica.org)
  • We investigated the severity and incidence of hematologic toxicity during intense chemotherapy processes in children treated with ALL IC-BFM 2009 protocol. (scirp.org)
  • Neutropenia is the most common hematologic toxicity and leads to life-threatening infections. (scirp.org)
  • There were not a statistical difference in therapeutic outcome among tumor types, performance status, sex, depth of neutropenia, or time from emergency department presentationto initiation of antibiotic therapy. (tjh.com.tr)
  • Factors including demographics, treatment history, management of febrile neutropenia and outcome were recorded. (icr.ac.uk)
  • 3 New tools are needed to predict unfavorable outcome at an early stage of the course of febrile neutropenia. (haematologica.org)
  • Analysis was performed to determine the incidence, severity, and outcome of neutropenia following ceftaroline administration. (asm.org)
  • Additionally, FN might have adverse affect on the overall treatment outcome due to dose reductions, treatment delays or chemotherapy discontinuation, especially in the adjuvant setting [11,12]. (scirp.org)
  • However, Radiotherapy and chemotherapy acquired a main role in this scenario. (springer.com)
  • In chronic neutropenia, the course may be less severe if the number of neutrophils is not extremely low, and the course can occasionally be intermittent (cyclic neutropenia). (online-vitamins-guide.com)
  • This success could be achieved by high-dose chemotherapy and supportive treatments. (scirp.org)
  • White blood cell colony-stimulating factors (CSFs) decrease the incidence of chemotherapy-induced febrile neutropenia (FN). (jnccn.org)
  • However, chemotherapy-associated toxicity remains as a problematic issue. (scirp.org)
  • The timing of docetaxel initiation in metastatic castrate-sensitive prostate cancer and the rate of chemotherapy-induced toxicity. (urotoday.com)
  • We checked for an association between TTC and febrile neutropenia (FN), toxicity-induced dose reduction, toxicity-induced treatment delay, and toxicity-induced treatment discontinuation. (urotoday.com)
  • Additionally, we believed that following current guideline recommendations for toxicity monitoring while on cephalosporin therapy did not provide for adequate early detection for the development of neutropenia in patients receiving ceftaroline. (asm.org)
  • Comparison of efficacy and toxicity of first line chemotherapy with or without epirubicin for patients with advanced stage soft tissue sarcoma. (koreascience.or.kr)
  • DelveInsight estimates suggest that the overall number of the cancer patients included in the report, which is at low risk of developing CIFN (Chemotherapy Induced Febrile Neutropenia) was found to be 45,471 in 2017. (saurashtranews.com)
  • Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. (semanticscholar.org)
  • BACKGROUND: Chemotherapy-induced febrile neutropenia is a medical emergency complicating the treatment of many cancer patients. (icr.ac.uk)
  • Colony-stimulating factors for the management of neutropenia in cancer patients. (qxmd.com)
  • Therefore, we recommend the Hosmer calculator for lung cancer patients receiving intermediate risk CIN chemotherapy as it lends to accurate but judicious use of CSF. (ajmc.com)
  • Adjuvant chemotherapy for early stage breast cancer patients has greatly improved both disease-free and overall survival by eliminating residual tumor cells after surgery ( 1, 2 ). (aacrjournals.org)
  • Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. (koreascience.or.kr)
  • From December 2014 through August 2016, a total of 181 adult patients who were prescribed oral targeted therapy or chemotherapy enrolled in a randomized study of adherence and symptom management at Massachusetts General Hospital Cancer Center. (jnccn.org)
  • Fungal infections are more likely to develop after prolonged periods of neutropenia and antibiotic-induced alterations of alimentary canal and respiratory tract flora. (annals.org)
  • Infections in patients with febrile neutropenia: epidemiology, microbiology, and peril stratification. (nippon-kan.org)
  • Bacterial infections in Pediatric patients with chemotherapy induced neutropenia. (pakmedinet.com)
  • Patients with PTCL seem to be endogenously immunosuppressed, even before the initiation of chemotherapy, and some patients can present with varicella zoster or opportunistic infections such as Pneumocystis jirovecii . (clinicaladvisor.com)
  • www.ncbi.nlm.nih.gov/pubmed/3181399?tool=bestpractice.com The normal range in black people has a lower limit of 1400/microlitre or 1.4 x 10^9/L. Common causes Infections are the most common causes of neutropenia in adults, followed by drug-induced neutropenias . (tripdatabase.com)
  • Determine the necessity of use of transdermal or parenteral opioid analgesics and IV antifungals or antibiotics for febrile neutropenia or infections in these patients. (knowcancer.com)
  • Preventing febrile neutropenia is essential because the condition itself can delay and interrupt cancer treatment, and cause serious infections, such as sepsis, and ultimately death. (ecmconnection.com)
  • The report also provides detailed current Chemotherapy Induced Febrile Neutropenia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. (saurashtranews.com)
  • Along with prior research, study findings support recently updated US practice guidelines indicating that PP should be administered the day after chemotherapy. (pai2.com)
  • While filgrastim-sndz and filgrastim have been shown to be highly similar with no clinically meaningful differences in reducing the incidence of febrile neutropenia in a randomized controlled trial setting where patient selection, conditions, and observations may be more ideal, comparative effectiveness for filgrastim versus filgrastim-sndz has not been studied to date using observations from real-world practice," wrote the authors of the study. (ajmc.com)
  • however, we observed several cases of severe neutropenia in our outpatient infectious disease practice believed to be associated with ceftaroline use. (asm.org)
  • Although it seems counterintuitive, neutropenic fevers are more likely to occur in the first cycle of chemotherapy compared with later cycles. (saurashtranews.com)
  • Therefore, patients should be assessed for the risk of developing FN in each cycle of chemotherapy and a regular risk assessment by using the PRS can be implemented in the monitoring process. (springer.com)
  • 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. (qxmd.com)
  • The guidelines suggest using granulocyte-colony stimulating factor (G-CSF) for febrile neutropenia (FN) as prophylaxis in chemotherapy protocols with the risk of 10-20% after assessment of patient's risk factors. (springer.com)
  • From of antibacterial prophylaxis in patients with chemotherapy- induced neutropenia. (nippon-kan.org)
  • We surveyed patients to assess how clinic visits for treatment with chemotherapy and the management of neutropenia affect their time and activities. (biomedcentral.com)
  • Monotherapy versus Dual Therapy Based on Risk Categorization of Febrile Neutropenic Patients. (ebscohost.com)
  • Cefepime monotherapy was compared with cefepime-plus-amikacin dual therapy for treatment of febrile neutropenic patients. (ebscohost.com)
  • Post of glycopeptides as for all practical purposes of primary pragmatic treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials. (nippon-kan.org)
  • A 2015 study   from Japan reported Neulasta used in women with stage 4 breast cancer reduced the risk of febrile neutropenia during chemotherapy by 98% compared to a placebo . (verywellhealth.com)
  • Neulasta is given once per every two- or three-week chemotherapy cycle. (verywellhealth.com)
  • Doctors usually reserve proactive use of Neulasta for only those patients considered at very high risk of developing chemotherapy-induced neutropenia. (amgen.com)
  • Specifically, one percent of patients in the Neulasta arm (6/463) developed febrile neutropenia compared with 17 percent of patients in the placebo arm (78/465). (amgen.com)
  • Patients and methods: Data from 76 patients with idiosyncratic drug-induced febrile neutropenia were retrospectively reviewed. (mdpi.com)
  • Recognition and management of drug-induced blood cytopenias: the example of drug-induced acute neutropenia and agranulocytosis. (tripdatabase.com)
  • Taking into account the above mentioned, the aims of this work were: To define a score to precise and evaluate PC and its severity, to define a useful algorithm for PC prevention, and to present some representative cases of drug-induced adverse events that afterwards required pharmacologic treatment to exemplify the PC evaluation. (scielo.org.ar)
  • TC chemotherapy can cause febrile neutropenia (FN) which can be serious and associated with treatment delays and dose reductions, thereby compromising treatment efficacy. (centerwatch.com)
  • I look forward to seeing future work by this group, particularly in the area of dose reductions and delays, as well as by oncology nurses who utilize the article to further their own work in neutropenia. (cancernetwork.com)
  • Research supports use of the Exergen professional TAT-5000 temporal thermometer as a noninvasive alternative to measure temperature in adult patients to detect febrile neutropenia, found research presented at the ONS 38th Annual Congress. (oncologynurseadvisor.com)